Synergistic inflammatory signaling in airway epithelial cells : control of expression levels of protease activated receptors and interleukin-8 release by unknown
Synergistic inflammatory signaling in airway epithelial 
cells: control of expression levels of protease-activated 
receptors and interleukin-8 release
Dissertation
Zur Erlangung des akademischen Grades
doctor rerum naturalium
(Dr. rer. nat.)
genehmigt durch die Fakultät für Naturwissenschaften
der Otto-von-Guericke Universität Magdeburg
von Dipl. -Pharm. Ewa Ostrowska
geb. am 09. November 1978 in Brzeg Dolny, Polen
Gutachter: Prof. Dr. Georg Reiser
       Privatdozent Dr. Frank Bühling
Eingereicht am: 25. September 2007
Verteidigt am: 31. März 2008
Danksagung
An dieser Stelle möchte ich all den Menschen von Herzen danken, die mir bei der 
Erstellung  dieser  Arbeit  geholfen  haben  und  meine  Arbeitszeit  einer  wertvollen 
Erinnerung machen werden.
Herrn  Prof.  Georg  Reiser  möchte  ich  ganz,  ganz  herzlich  für  Betreuung, 
Unterstützung, Förderung und besonders für den Glauben an mich danken.
Frau Dr. Sokolova möchte ich vor allem dafür danken, dass durch die zahlreichen 
Diskussionen mit ihr, meine Arbeit die jetzige Form annehmen konnte.
Allen Kolleginnen und Kollegen, Mitarbeitern des Instituts für Neurobiochemie, die 
ich durch meine Arbeit kennenlernen durfte, danke ich ganz herzlich für alles was ich von 
Ihnen  gelernt  habe  und  was  ich  mit  ihnen  erlebt  habe.  Vielen  Dank  für  jede  Hilfe, 
Unterstützung und für jedes Lächeln.
Table of content
1.1.2 Agonists of PARs.                                                                                                 ...............................................................................................3  
1.1.3 PAR distribution in human tissue and cell types.                                                  ................................................6  
1.1.4 PAR-3 signaling                                                                                                    ..................................................................................................7  
1.2 Inflammatory mediators and processes in lung.                                                           .........................................................8  
1.2.1 The involvement of epithelium in inflammatory processes in lung.                   .................10  
1.2.2 The role of cytokines IL-8 and TGF-β1 in airway inflammation.                       .....................11  
1.3 PARs in respiratory disorders.                                                                                   .................................................................................12  
1.3.1 PAR agonists and inactivators in lung.                                                               .............................................................12  
1.3.2 Role of PARs in pathophysiology of lung tissue.                                               .............................................15  
1.4 Aims of the project and outline of the present study.                                                 ...............................................18  
2 Materials and Methods                                                                                                   .................................................................................................20  
2.1 Materials                                                                                                                     ...................................................................................................................20  
2.1.1 Chemicals and reagents                                                                                       .....................................................................................20  
2.1.2 Kits                                                                                                                      ....................................................................................................................21  
2.1.3 Antibodies                                                                                                           .........................................................................................................21  
2.1.4 Laboratory instruments                                                                                        ......................................................................................22  
2.1.5 Buffers and solvents                                                                                            ..........................................................................................22  
2.2 Methods                                                                                                                      ....................................................................................................................24  
2.2.1 RNA isolation                                                                                                      ....................................................................................................24  
2.2.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)                          ........................25  
2.2.3 Reverse transcription and real-time PCR                                                            ..........................................................26  
2.2.4 Agarose gel electrophoresis of DNA                                                                   .................................................................27  
2.2.5 Agarose gel electrophoresis of RNA                                                                   .................................................................28  
2.2.6 DNA Sequencing                                                                                                 ...............................................................................................28  
2.2.7 Quantification of nucleic acids                                                                            ..........................................................................28  
2.2.8 Cloning                                                                                                                ..............................................................................................................29  
2.2.9 Cell culture                                                                                                          ........................................................................................................32  
2.2.10 Protein chemistry                                                                                               .............................................................................................34  
2.2.11 IL-8 protein determination                                                                                ..............................................................................35  
2.2.12 Immunocytochemistry                                                                                       .....................................................................................35  
2.2.13 Cytosolic Ca2+ measurements                                                                          ........................................................................35  
2.2.14 Confocal imaging                                                                                              ............................................................................................36  
2.2.15 Analysis of fluorescence intensities                                                                  ................................................................36  
2.2.16 Statistics                                                                                                             ...........................................................................................................37  
3 Results                                                                                                                              ............................................................................................................................38  
3.1 Expression of the PARs in A549 cells and other lung epithelial cells.                      ....................38  
3.1.1 Detection of PARs by RT-PCR.                                                                          ........................................................................38  
3.1.2 Detection and localization of PARs by immunocytochemistry.                         .......................39  
3.1.3 PAR agonist-mediated mobilization of Ca2+ in A549 cells.                              ............................40  
3.2 Evaluation of PARs activation by trypsin isoforms in airway epithelial cells.          ........42  
3.3 Modulation of PAR expression and synthesis of cytokines by exposure of the cells 
to inflammatory mediators and / or PAR activation.                                                       .....................................................45  
3.3.1 Effect of inflammatory mediators on the expression of PARs, IL-8 and TGF-β1 
in A549 cells.                                                                                                                ..............................................................................................................45  
3.3.2 Modulation of PAR, IL-8 and TGF-β1 expression by continuous PAR 
activation in A549 cells.                                                                                               .............................................................................................47  
3.3.3 The influence of concomitant stimulation with PAR agonists and LPS on PAR 
expression in A549 cells.                                                                                              ............................................................................................49  
3.3.4 Modulation of IL-8 synthesis in airway epithelial cells by PAR activation with 
simultaneous exposure to LPS.                                                                                    ..................................................................................51  
3.3.5 The influence of PAR activation and concomitant stimulation with LPS on 
TGF-β1 expression in A549 cells.                                                                                ..............................................................................55  
3.4 Role of MAPKs in PAR-mediated IL-8 release from A549 cells.                             ...........................56  
3.4.1 Influence of thrombin, PAR-2 AP and LPS on MAPK phosphorylation in 
A549 cells.                                                                                                                    ..................................................................................................................56  
3.4.2 Inhibition of ERK1/2 or of JNK decreases the production of IL-8 in response to 
thrombin and PAR-2 AP, either alone or together with LPS.                                      ....................................58  
3.5 PAR-3 signaling                                                                                                         .......................................................................................................59  
4 Discussion                                                                                                                        ......................................................................................................................71  
4.1 Functional expression of PARs in airway epithelial cells.                                         .......................................71  
4.2 Evaluation of PAR activation by trypsin isoforms in airway epithelial cells.           .........71  
4.3 Inflammatory mediators LPS, TNF-α, IL-8 and PGE2 regulate PAR expression in 
A549 cells.                                                                                                                        ......................................................................................................................73  
4.4 Continuous PAR activation and simultaneous exposure to endotoxin modulate PAR 
expression in airway epithelial cells.                                                                                ..............................................................................76  
4.5 PAR activation stimulates and potentiates the LPS-induced IL-8 production.          ........79  
4.6 Inflammatory mediators and PAR activation induce TGF-β1 production.                ..............81  
4.7 PAR-mediated signaling pathway in respiratory epithelium. Distinct role of 
MAPKs in PAR-induced IL-8 release.                                                                             ...........................................................................81  
4.7.1 Role of PAR-3 in IL-8 production and the signaling pathway involved in this 
process.                                                                                                                         .......................................................................................................................84  
4.8 Conclusions                                                                                                                ..............................................................................................................86  
5 Abstract                                                                                                                           .........................................................................................................................89  
6 Zusammenfassung                                                                                                          ........................................................................................................92  
7 References                                                                                                                        ......................................................................................................................95  
8 Abbreviations                                                                                                                  ................................................................................................................96  

Introduction
1. Introduction
1.1 The family of protease-activated receptors (PARs).
The “history” of protease-activated receptors (PARs; more correctly, but less commonly 
referred to as proteinase-activated receptors) is relatively young. Only in the early nineties 
PARs were cloned and their unique activation mechanism was described . There are 4 
subtypes of PARs, PAR-1, PAR-2, PAR-3 and PAR-4, named in chronological order of 
their discovery. PAR-1, formerly known as the thrombin receptor, was identified using 
RNA derived  from thrombin-responsive  cells   and is  still  the one of  the  four  family 
members  which is  the best  characterised.  Three  years  later  the second proteolytically 
activated receptor, PAR-2, was cloned from a mouse genomic library, and subsequently 
found to be activated by trypsin .  The third family member, PAR-3, was identified as a 
second thrombin receptor in PAR-1 knockout mouse cells , cloned and characterized  . 
PAR-4 was cloned following database search using conserved domains of other PARs. 
PAR-4 was identified  in PAR-3 deficient  mouse platelets  with persisting response  to 
thrombin . 
All the PAR genes, in human and mouse, share a similar two exon structure with a very 
long intron of 4-22 kb in case of PAR-1-3 and only 0.25 kb for PAR-4. PAR-1, PAR-2 
and PAR-3 genes are located closely together on a single chromosome in humans (5q13) 
and  mice  (13D2),  whereas  the  gene  for  PAR-4 is  located  separately  in  both  species 
(chromosome 19p2 and 8B3.3, respectively) .
1.1.1 Mechanism of activation and signal transduction.
PARs consist of the typical 7-transmembrane helices connected by 3 extracellular and 3 
intracellular loops together with an extracellular N-terminal and intracellular C-terminal 
domain (Fig. 1.1). Despite the fact that these receptors belong to a large superfamily of G 
protein-coupled receptors, the activation mechanism is very distinct from that of other 
receptors from this family. The mechanism of receptor activation involves cleavage of the 
receptor at a specific site within the extracellular amino terminus, called “activation site”, 
thus  unmasking  a  new  N-terminal  “tethered”  ligand.  The  “tethered”  ligand  binds 
intramolecularly to the receptor resulting in the initiation of signal transduction (Fig. 1.1). 
Six  or  more  specific  amino  acid  residues  within  the  newly  exposed  tethered  ligand 
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interact with extracellular loop 2 (Lerner et al., 1996). Thus, PARs are peptide receptors 
carrying their own ligands, which remains cryptic until unmasked by receptor cleavage .
Ultimately,  the activated receptor  interacts  with heterotrimeric G proteins,  which 
catalyze the exchange of GDP for GTP on the α-subunit of the G-protein. It results in 
transducing numerous intracellular  signals, e.g. stimulation of phospholipase C (PLC)-
catalyzed hydrolysis of polyphosphoinositides. PLC activation causes the formation of 
diacylglycerol  and  of  inositol  1,4,5-trisphosphate  (InsP3)  with  further  mobilization  of 
intracellular Ca2+ and activation of protein kinase C. This triggers activation of mitogen-
activated protein kinases (MAPKs) and other Ca2+-modulated kinases.
Figure 1.1:  Activation of PARs. The protease cleaves irreversibly the PAR at the “activation 
site”,  unmasking a new N-terminus acting as a tethered ligand.  This ligand interacts  with the 
second extracellular  loop  of the  receptor  initiating  G protein  coupling.  A synthetic  activating 
peptide (AP) derived from the N-terminal sequence of PAR is able to activate the receptor in the 
absence of protease-mediated cleavage of the N terminus.
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PARs are activated by an irreversible mechanism, and once cleaved, are destined for 
lysosomal  degradation.  Once  activated,  the  receptors  rapidly  uncouple  from  the 
transmembrane signaling and internalize by a phosphorylation-dependent  mechanism . 
The internalized receptor is mostly targeted to lysosomes for degradation and only few 
molecules  recycle  back to the cell  surface  but  remain inactive.  Resensitization of the 
receptor involves mobilization of the intracellular receptor pools, the Golgi apparatus and 
vesicles, where PARs are stored. Alternatively, PARs are synthesized de novo . The level 
of expression of receptors at the cell surface is a balance between removal by endocytosis 
and replenishment by mobilization of intracellular pools .
1.1.2 Agonists of PARs.
Three of the PAR receptors can be activated by thrombin, the main effector protease of 
the coagulation cascade  .  Thrombin is a serine protease generated at  sites of vascular 
injury, produced from its precursor molecule prothrombin by the coagulation factor Xa in 
association with factor Va. Further, thrombin converts fibrinogen to fibrin which forms 
clots . Apart from the function in coagulation, thrombin has multiple biological effects, 
including  platelet  aggregation  and  endothelial  cells  proliferation,  mostly  via  PARs  . 
Thrombin exhibits high potency to activate PAR-1 and PAR-3, whereas PAR-4 activation 
requires 10-100 fold higher concentration. This apparently results from different primary 
structures  of  the  receptors.  The  extracellular  amino  terminus  of  PAR-1  and  PAR-3 
contains a sequence of negatively charged residues, the so called “hirudin-like domain” 
that is distal to the thrombin cleavage site. This domain binds to an exosite I of thrombin 
to cause allosteric activation of thrombin and thus promotes efficient receptor activation. 
That explains thrombin’s potency at its receptor. The name of this region of the receptor 
comes from the fact that it resembles a domain of the leech anticoagulant hirudin, which 
inhibits thrombin by binding to its anionic site .
Differences  in  potency  of  thrombin  to  activate  different  PARs  have  interesting 
functional consequences. For example, human platelets express both PAR-1 and PAR-4, 
what allows them to respond to a broad range of concentrations of thrombin in a regulated 
manner. PAR-1 mediates responses to low concentrations of thrombin, whereas in the 
absence  of  PAR-1  function,  PAR-4  can  mediate  platelet  activation  but  only  at  high 
thrombin concentrations.  However,  the functional  expression of PAR-3, in contrast  to 
PAR-1 and PAR-4, was not detected in human platelets, what suggests that in humans 
PAR-3 does not play a major role for platelet activation, in contrast to the mouse system.
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Other members of the coagulation cascade, factors Xa and VIIa, can also activate 
PAR-1 or PAR-2 .
Interestingly, activated protein C (APC), the major protease of anticoagulation pathway, 
can also trigger cellular responses via PAR-1 . However, very high concentrations of APC 
are required for the PAR-1 cleavage .
Another main PAR agonist, trypsin, activates PAR-2 , PAR-4  and PAR-1 . Trypsin 
is  secreted from pancreas  into the small  intestine as inactive  trypsinogen,  where it  is 
activated  by  enteropeptidase.  The  major  two  trypsinogen  isoforms  are  cationic  and 
anionic trypsinogens and the third less abundant form mesotrypsinogen, which possesses 
resistance  to  common trypsin  inhibitors  .  Trypsin  was thought  to  be restricted to  the 
pancreas. However, now several studies have demonstrated the presence of trypsin in a 
variety of tissues such lung, brain, kidney, pancreas, spleen and cells such as leukocytes, 
neurons, epithelial and endothelial cells .
Mast cells  tryptase,  an important  inflammatory mediator,  detected in fluids from 
inflamed tissues is also a PAR-2 activator .
Cathepsin  G  from  neutrophils  is  a  potential  activator  of  PAR-4  .  Neutrophil 
proteinase 3 can activate  PAR-2 . Granzyme  A, released by activated T lymphocytes 
appears to activate the thrombin receptor PAR-1 .
Only recent  reports  show that  matrix  metalloprotease-1 (MMP-1) in  the stromal 
tumor can alter the behaviour of cancer cells through PAR-1 to promote cell migration 
and  invasion  .  Furthermore, tumor-derived  MMP-1  cleaves  endothelial  PAR-1,  thus 
generating a prothrombotic and proinflammatory cell adhesion .  However, the ability of 
MMPs to activate PARs needs to be further evaluated systematically.
An interesting aspect  is that  a number  of non-mammalian proteases  from mites, 
bacteria, and fungi have been found to activate PARs in mammalian cells.  For instance, 
dust  mite  Dermatophagoides  pteronyssinus  (Der  p)  produce  serine proteases,  cysteine 
proteases, and metalloproteases that are allergens in airway epithelium. It has been shown 
that these proteases can act via PAR. The effects of the proteases Der p3 and Der p9, Der 
p1 is mediated by PAR-2 .
Similarly, proteases from bacteria  Porphyromonas gingivalis  can activate PAR-1, 
PAR-2 and PAR-4 . Proteases from fungal extract might activate cells through PAR-2 .
Because of the unique activating mechanism of PARs, it is possible to directly use 
the synthetic peptides (activating peptides: AP) mimicking the tethered ligand sequence to 
activate the receptor without the proteolytic cleavage. The advantage of applying these 
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small peptides is manifested in 1) specificity, what gives the opportunity to avoid the use 
of  proteases,  which  have  many  additional  biological  effects,  and  2)  possibility  of 
development of antagonists, for which APs serve as a template. On the other hand the 
APs have some disadvantages limiting particular implications: 1) there is a low potency 
of  APs.  They  require  concentrations  in  excess  of  minimally  several  micromolar 
concentrations; 2) peptides are not always specific, e.g. SFLLR-NH2, PAR-1 AP derived 
from the human PAR-1 sequence can activate both PAR-1 and PAR-2 ; 3) there is no 
reliably effective AP for PAR-3 known.
An overview of the cleavage sites and the unmasked new terminus that function as 
tethered ligand on human and murine PARs is  presented  in  Table  1.1.  The synthetic 
peptide mimics the tethered ligand sequence and functions as an agonist independent of 
receptor cleavage.
PAR-1 PAR-2 PAR-3 PAR-4
Activator Thrombin>Trypsi
n
Trypsin Thrombin Thrombin=Trypsin
Cleavage 
site, human R
41↓SFLLRN R34↓SLIGVK K38↓TFRGAP a R47↓GYPGQV
Cleavage 
site, murine R
41↓SFFLRN R38↓SLIGRL K37↓SFNGGP a R59↓GYPGKF
Improved 
agonist TFLLR tc-LIGRLO AYPGKF
Table 1.1: Summary of general  properties  of  “tethered”  ligand of human and murine PARs. 
Symbol  abbreviation  for  amino  acids  are  numbered  accordingly,  beginning  from  the  amino 
terminus of the translated protein sequence. Appropriate cleavage site (↓) by activating proteases 
and  predicted  TLS  after  cleavage,  what  sequence  serves  for  synthetic  peptides  analogues. 
Sensitivity to thrombin or trypsin is a basic defining feature of the PAR subtypes.  aInactive as 
peptide agonist. TLS, tethered ligand sequence.
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1.1.3 PAR distribution in human tissue and cell types.
As it is shown in Table 1.2, PARs are receptors with widespread distribution and are 
abundant in almost every tissue in the human body. Cells can express more than one PAR 
family member and more than one may be thrombin-responsive.
Table 1.2: Localization of PARs in human tissues.
Organ (tissue and cell type) References
PAR-1
Brain (astrocytes, neurons)
Eye (corneal cells)
Lung  (fibroblasts,  alveolar  macrophages, 
epithelium, smooth muscle)
Pancreas
Liver 
Epidermis (keratinocytes, fibroblasts)
Vascular  system  (endothelial  umbilical  cells, 
smooth muscle)
Platelets
Cell of immune system (monocytes, macrophages)
PAR-2
Brain (neurons, astrocytes)
Eye (corneal cells)
Lung (epithelium, smooth muscle, fibroblasts)
Heart
Pancreas
Liver
Intestine (epithelium, nonvascular smooth muscle)
Kidney
Prostate (epithelium, myofibroblats)
Uterus (smooth muscle)
Vascular  system  (smooth  muscle  cells, 
endothelium)
Epidermis (keratinocytes, endothelial cells)
Cell of immune system (macrophages, neutrophils, 
eosinophils)
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Organ (tissue and cell type) References
PAR-3
Bone marrow
Lung (fibroblasts, epithelium, smooth muscle)
Heart
Pancreas
Liver
Small intestine
Vascular system (endothelial umbilical cells, smooth 
muscle)
Cells of immune system (monocytes, macrophages, 
neutrophils)
PAR-4
Lung (epithelium, smooth muscle)
Pancreas
Liver
Small intestine
Thyroid
Prostate
Vascular system (endothelial cells, smooth muscle)
Platelets
1.1.4 PAR-3 signaling
The knowledge about PAR-3 signaling and its functional role, in contrast  to the 
other members of the PAR family, is still unclear and confined to relatively few findings 
that have been published until  now. A specific feature of this  receptor  is its different 
species-specific  susceptibility  and  consequently  physiological  function  in  mouse  and 
human. The responsiveness of human PAR-3 to thrombin was confirmed in heterologous 
expression systems, in COS7 cells and Xenopus oocytes . However, the experiments on 
murine PAR-3, overexpressed in COS7 cells as well as platelets from PAR-4 deficient 
mouse, demonstrated that murine PAR-3 itself does not mediate intracellular signaling 
but serves as a cofactor for PAR-4 cleavage .  It might indicate that  during evolution, 
murine PAR-3 has lost its ability to function autonomously. Additionally, the independent 
differential expression patterns of PAR-3 and PAR-4 in these two species, human and 
mouse, further indicate differences in the functional role of PAR-3. Particularly platelets, 
where  thrombin  is  a  potent  activator,  represent  a  good  model  of  PAR-3  signaling. 
Consistently,  human and mouse platelets display distinct PAR-3 expression as well as 
signaling. Murine PAR-3 is necessary for complete thrombin-mediated platelet activation, 
however its role seems to be restricted to act as cofactor for PAR-4 . In human platelets, 
7
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thrombin is signaling through the activation of PAR-1 and PAR-4, whereas PAR-3 is not 
involved in this process .
The presence of a considerably shorter C-terminal tail in PAR-3 (15 amino acids for 
hPAR-3) than in other PARs (about 40 amino acids) suggests that PAR-3 signaling and 
desensitization differs from that of other PARs. However, there are no investigations of 
this aspect available until now. Furthermore, the great obstacle in the extension of studies 
on  PAR-3  signaling  is  the  lack  of  PAR-3  selective  agonist  or  antagonist.  Synthetic 
peptides that mimic the putative tethered ligand of PAR-3 were found to be inactive in 
terms  of  PAR-3 activation  .  However,  there  are  studies  reporting  these  peptides  that 
mimic the putative tethered ligand of human and murine PAR-3 may activate PAR-1 and 
PAR-2 . Nevertheless, our and other groups previously showed that the PAR-3-activating 
peptide is able to induce cellular responses in rat astrocytes , human smooth muscle cells 
and  Jurkat  T  cells  .  Therefore,  the  issue  of  selective  agonists  for  PAR-3  remains 
controversial.
A most recent report discloses interesting findings about the function of endothelial 
PAR-3  .  The  authors  show  that  PAR-3  can  form  heterodimers  with  PAR-1.  These 
PAR-1/3 dimers are formed constitutively and, upon activation, induce signaling distinct 
from PAR-1/1 homodimers, involving coupling to Gα13. PAR-3 functions as an allosteric 
regulator of thrombin to enhance PAR-1 cleavage what leads  to increased endothelial 
permeability.
However, PAR-3, particularly of human origin has remained largely unexplored 
and leaves plenty of questions open. The abundant distribution of this receptor in human 
tissues  indicates  the  high  biological  relevance  of  PAR-3  activation.  Therefore  the 
unequivocal establishment of a signaling cascade connected to PAR-3 without crosstalk 
to other PARs underlines the eminent importance of PAR-3.
1.2 Inflammatory mediators and processes in lung.
Inflammation can be broadly defined as nonspecific protective reaction of vascular 
tissue to injury, extremely important for the clearance of exogenous toxins and pathogens. 
This  process  is  accompanied  by  vasodilation,  increased  blood  flow,  enhanced 
permeability that augments the recruitment of inflammatory cells and delivery of plasma 
proteins to the site of injury. In general, this process is self-limiting and leads to a return 
to the normal state .
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The early-phase of the inflammatory reaction is characterized by the rapid activation 
of airway mast cells and macrophages which release proinflammatory mediators such as 
early cytokines, TNF-α and IL-β1, histamine and eicosanoids, as well as reactive oxygen 
species,  which  induce  contraction  of  airway  smooth  muscle,  mucous  secretion, 
vasodilation  and  enhanced  permeability.  These  changes  maximize  the  recruitment  of 
peripheral blood cells: eosinophils, basophils, neutrophils, lymphocytes, and monocytes 
into inflamed airways. The involvement of these cells initiates the late-phase reaction and 
results  further  in  adhesive  interactions  between  circulating  inflammatory  and 
microvascular  endothelial  cells  via  the  production  of  proinflammatory  mediators, 
cytokines, chemokines and the expression of cell surface adhesion molecules . These late-
phase reactions represent the model for studying the mechanisms of chronic inflammation 
in  asthma.  In  asthma,  the  airway  wall  is  infiltrated  with  mononuclear  cells  and 
eosinophils.  Eosinophilic  inflammation  is  the  characteristics  for  asthma  and  once 
eosinophils have been recruited to the respiratory tract, their activation leads to secretion 
of toxic products like eosinophilic cationic protein, neurotoxin and free radicals, but also 
growth factors, elastase, metalloproteases and cytokines. The release of these eosinophilic 
mediators  results  in  vascular  leakage,  hypersecretion  of  mucus,  smooth  muscle 
contraction,  epithelial  shedding,  and  eventual  irreversible  airway  hyperresponsiveness 
and also initiates the process of remodeling. Therefore, eosinophils are able to play an 
important part in both, boost of airway inflammation and remodeling . Other cells like T-
cells, macrophages, neutrophils and mast cells are also variably increased in the inflamed 
airways. Mast cells localize within the bronchial smooth muscle in asthma. They secrete 
tryptase, histamine, prostaglandin (PG) D2, leukotriene (LT) C4, as well as numerous pro-
inflammatory  cytokines  like  IL-4,  IL-5,  IL-13,  IL-6,  TGF-β1  and  TNF-α,  which 
contribute to all features of asthma like bronchoconstriction, mucus secretion, mucosal 
oedemas and airway remodeling .  The evidence of up-regulation of TNF-α in asthma 
suggests that mast cells, as a source of this cytokine, play an important role in initiating 
and maintaining the inflammatory response in asthma  .  Another study shows that  mast 
cells both release and respond to TNF-α what indicates, that there is a positive autocrine 
loop which leads to augmentation of mast cell activation and further production of TNF-α 
and other cytokines . Therefore, TNF-α, as a potential mediator of severe asthma, serves 
nowadays as target for development of novel therapies applied in asthma .
As  it  is  shown in  Figure  1.2,  not  only  migratory  cells  of  the  airways,  such  as 
lymphocytes,  macrophages,  but  also resident  cells  like fibroblasts,  epithelial  cells  and 
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even bronchial smooth muscle cells, are involved in pathological states such as asthma 
and become activated during acute inflammation.
Figure 1.2: Network of inflammatory stimuli and responses in airways .
1.2.1 The involvement of epithelium in inflammatory processes in lung.
Epithelium was considered to act mainly as a  natural physical  barrier  to external 
agents  like  bacteria,  viruses  and toxic  substances participating  in  reactions  protecting 
against injuries such as mucociliary clearance and removal of noxious agents. However, 
recently it has been shown that epithelial cells,  in addition to the cells of the immune 
system, actively participate in inflammatory reactions . The epithelial surface regulates a 
variety  of  biologic  reactions  including  protection  against  injuries  and  remodeling 
processes through the secretion of extracellular matrix proteins and the interaction with 
the other cells. Exposure of epithelial cells to deleterious factors like allergens, bacteria, 
pollutants,  and  to  endogenous  proinflammatory  factors,  such  as  the  early  cytokines 
interleukin-1β (IL-1β) and (TNF-α), triggers defence mechanisms and secretion of pro- 
and  anti-inflammatory  mediators  including  cytokines,  growth  factors  and 
metalloproteases . Epithelial cells represent also a target for cytokines and growth factors 
acting in a paracrine manner.
10
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1.2.2 The role of cytokines IL-8 and TGF-β1 in airway inflammation.
In general, cytokines are released by a variety of cells and play a highly important 
role in the immune system. They are produced mostly along with other cytokines in the 
patterns characteristic for particular organ dysfunctions. They are characterized by a wide 
pleiotropy (a single type of cytokine molecule  can produce many diverse effects)  and 
redundancy (overlapping functions, different cytokines can perform the same actions). 
Moreover,  the effect  of one particular  cytokine may be influenced by other cytokines 
released  simultaneously,  inducing  synergistic  or  antagonistic  effects.  Cytokines  can 
induce the expression of receptors that may in turn change the properties of participating 
cells, stimulate their own synthesis or production of different cytokines, that can cause 
positive or negative feedback . One of the important members of the cytokine family is 
the chemokine interleukin-8. IL-8 is a secretory product of numerous cell types including 
monocytes,  neutrophils,  basophils,  eosinophils,  fibroblasts,  alveolar  macrophages, 
bronchial epithelial cells, airway smooth muscle cells (ASM). IL-8 is a potent chemo-
attractant for neutrophils and comprises part  of the inflammatory response induced by 
microbial  infection.  This chemokine mediates  its  effect  through CXCR2 to picomolar 
IL-8  concentration  and  to  higher  concentrations  of  IL-8  through  CXCR1  .  The  IL-8 
production was highly up-regulated in patients with asthma, COPD and cystic fibrosis  . 
Therefore elevated  IL-8 was identified as a  marker  implicated in the development  of 
airway  inflammation.  Moreover,  elevated  expression  of  IL-8  together  with  another 
cytokine,  transforming  growth  factor-β1  (TGF-β1),  has  been  observed  in  respiratory 
disorders. The release of both cytokines was enhanced in bronchiolar epithelium from 
smokers with COPD compared with those levels  without  COPD and in patients  with 
asthma or microbiologically positive pneumonia  .  Furthermore, an increased activity of 
TGF-β1 was found in the lung of patients with chronic bronchitis when compared with 
healthy control subjects .
However, the action of TGF-β is very complex and not clear until now. TGF-β1 is a 
potent  fibrotic  cytokine  and  induces  pulmonary  fibrosis  .  In  addition,  TGF-β1  is  an 
immunomodulatory cytokine. This factor seems to play a central role in regulating the 
balance between burst and resolution of inflammatory responses. The state of activation 
and differentiation of the target cells,  the presence of other stimuli  and the functional 
consequences of inappropriately large or small amounts of TGF-β1 are different at each 
site . For example, low concentrations of active TGF-β1 are required to maintain alveolar 
homeostasis and prevent the development of emphysema, whereas high concentrations 
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can induce emphysema, apparently through a pathway that involves apoptosis of alveolar 
epithelial cells . In response to lung injury, activation of TGF-β1 on the apical surface of 
the  alveolar  epithelium  inhibits  the  increase  in  macrophage  protease  (MMP12) 
expression. At the same time, on the basolateral surface TGF-β1 induces production of 
collagen and other extracellular matrix proteins from alveolar fibroblast and contributes to 
influx of clotting factors and other proteins from the serum . Therefore it appears that 
TGF-β1 contributes to limiting the damage and initiating the process of alveolar repair. 
Furthermore, TGF-β1 is a chemoattractant for mast cells and is released by ASM after 
exposure to tryptase from mast cells and activation of PAR-2, providing a mechanism of 
an  autoactivation  loop involving  smooth  muscle,  TGF-β1 and mast  cells  .  Moreover, 
animal studies show that deficiency of the TGF-β1 gene in mouse causes a multifocal, 
inflammatory  cell  response  and  tissue  necrosis,  leading  to  organ  failure  and  death  . 
Delayed wound healing was observed in TGF-β1 immunodeficient mouse  .  Similarly, 
data from in vitro studies showed that TGF-β1 increases the speed of epithelial repair and 
even suppresses apoptosis  .  Thus, TGF-β1, a fibrogenic and immunomodulatory factor, 
plays multifunctional roles contributing to airway repair and remodeling and is involved 
in  complex  processes  associated  with  the  development  of  respiratory  disorders  like 
asthma .
1.3 PARs in respiratory disorders.
1.3.1 PAR agonists and inactivators in lung.
There are many potential PAR activators of endogenous as well as exogenous origin 
that can interact with PARs in airway tissue. Especially in the diseased lung, increased 
activity of potential biological activators of PARs has been detected. In acute and chronic 
inflammation,  vascular  leakage  results  in  the  accumulation  of  plasma  proteins  in  the 
airways and activation of coagulation . The consequence is an increased activity of the 
coagulation  protease  thrombin,  the  main  PAR-1  activator.  Thrombin  was  found  in 
bronchoalveolar lavage fluid (BALF) and in the sputum of asthmatic patients that was 
significantly higher than in non-asthmatic subjects . Increased thrombin activity was also 
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detected  in  BALF of  patients  with  acute  lung  injury  and  chronic  lung  diseases  with 
characteristics of pulmonary fibrosis .
Fibrinolysis-related  proteases  (plasmin,  tissue  plasminogen  activator,  urokinase) 
exhibit small effects on the uninflamed airways, but can be recruited into the lung during 
pulmonary  oedema  and  inflammation  . It  has  been  shown  that  plasmin  can  display 
mitogenic effects via PAR-1 activation on lung fibroblasts .
The  airways  of  patients  with  chronic  airway  diseases  contain  another  PAR-2 
activator, human trypsin-like protease (HAT) . The enzyme is localized to epithelial cells 
and is released into the airway wall during airway disease where it mediates regeneration 
and  remodeling  by  stimulation  of  fibroblast  proliferation  through  a  PAR-2-mediated 
pathway .
Another  well  established  activator  of  PAR-2,  trypsin,  co-localizes 
immunohistochemically in epithelial cells with PAR-2 . The ability of trypsin to activate 
PAR-2 as well as PAR-1 in the respiratory tract has been confirmed by in vitro studies. 
However, the knowledge about the action and importance of trypsin outside the pancreas, 
in vivo is still incomplete .
In the inflamed airways, there is also elevated activity of proteases secreted into the 
cellular  space  by  migratory  inflammatory  cells,  which  have  an  effect  on  PARs.  The 
asthmatic epithelium is characterized by mast cell infiltration and release of the potent 
PAR-2 activator tryptase upon cell degranulation . Similarly in nasal lavage fluid and in 
BALF  tryptase  levels  were  higher  in  asthmatics  and  patients  with  allergic  rhinitis  . 
Released  into  diseased  airways,  tryptase  regulates  homeostatic  functions  in  lung  by 
activating PAR-2, for example in fibroproliferative responses .
Various airway cells express other catalytically active proteases, like tryptase Clara, 
miniplasmin, but their ability to cleave PARs has not yet been determined . Relatively 
new findings show that MMPs can act via PARs  .  MMPs are actively secreted by the 
airway epithelium, alveolar  macrophages,  and neutrophils  during airway inflammation 
and  remodeling  and can  cleave  biologically  active  peptides,  such  as  endothelins  and 
calcitonin gene-related peptide 
There is increasing evidence that inhaled airborne allergens also play an eminent 
role in activation of respiratory PARs by contributing to elevated levels of proteases in 
airways. Recent reports show that the effect of airborne allergens from house dust mite 
faecal pellets or fungi stimulate the release of pro-inflammatory cytokines through the 
activation of PARs. As presented in Table 1.3, house dust mite allergen Der p 1, Der p 3 
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and Der  p 9-induced release of  proinflammatory  cytokines  from respiratory epithelial 
cells is, in part, mediated by activation of PAR-2 . Mold protease, Pen c 13, exhibits its 
proteolytic  activity  by cleavage  of  PAR-1 and PAR-2 in airway epithelial  cells  what 
mediates IL-8 release  .  The bacterial protease serralysin elicits inflammatory responses 
via PAR-2 in lung  squamous cell carcinoma  .  On the contrary, bacterial proteases like 
thermolysin and  P. aeruginosa elastase function as a disabling protease for PAR-1 and 
PAR-2,  respectively  .  This  may  alter  the  host’s  innate  defense  mechanisms  and 
respiratory functions.
Although proteolysis is the physiological mechanism for PAR activation, proteases 
can  also  inactivate  receptors.  Neutrophil  proteases  such  as  elastase,  cathepsin  G, 
proteinase-3,  that  contribute  to  chronic  obstructive  pulmonary  disease,  can  inactivate 
PAR-1 and PAR-2 preventing activation of PARs by other proteases . Similarly, human 
PAR-3 is disabled by elastase and cathepsin G . On the other hand, neutrophil proteinase 
3 can activate PAR-2 and cathepsin G activates PAR-4 . 
The effect of all these proteases becomes notably important in diseases involving 
airway inflammation. When the level of these pro-inflammatory proteases of the immune 
system and coagulation-related proteases is elevated in the extracellular space, PARs can 
be  activated.  The  consequences  of  PAR-mediated  effects  might  have  supplementary 
impact on the development of airway inflammation. 
Concluding, several PAR agonists that are able to activate epithelial PARs occur in 
the airways, as summarized in Table 1.3. Thrombin, factor VIIa and Xa, originated from 
the blood circulation or proteases released by cells of the immune system e.g. tryptase 
have easy access to the airway epithelium during inflammatory reaction or disruption of 
the blood barrier.  Even epithelial  cells  themselves  are  an important  source of a PAR 
agonist, trypsin.
Table 1.3: Sources of proteases in lung and the PAR subtype activated by these proteases.
Protease Source PAR subtype
Thrombin Blood PAR-1, PAR-3, PAR-4
Trypsin Epithelium PAR-1, PAR-2, PAR-4
Mast cell tryptase Mast cells, basophils PAR-2
Factor Xa Blood PAR-1, PAR-2
Factor VIIa Blood PAR-2
Neutrophil proteinase 3 Neutrophils PAR-2
Cathepsin G Monocytes, neutrophils PAR-4
HAT Epithelium PAR-2
MMP Epithelium,  alveolar PAR-1
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macrophages
Der p1, p3, p9 Dust mite PAR-2
Serralysin Bacteria PAR-2
Pen c 13 Mold PAR-1, PAR-2
1.3.2 Role of PARs in pathophysiology of lung tissue.
Many of  the  cellular  effects  of  proteases  have  been  shown to  be  mediated  via 
activation PARs. All 4 PARs are widely distributed throughout the respiratory system and 
are present on nearly all cells involved in inflammatory states in human airways.
Activation of PARs modulates airway tone in vitro, but the functional response is 
dependent on the species examined, the cell and tissue type. For example, PAR-2 induces 
relaxation in isolated murine, rat and guinea pig bronchial rings and inversely, stimulates 
contraction in human bronchial rings . Moreover, activation of PARs on airway cells can 
stimulate  proliferation  and  promote  remodeling   by  stimulating  the  release  of  the 
mitogenic mediator platelet-derived growth factor (PDGF), MMP-9 or procollagen . PAR 
activation on fibroblasts, mast cells, eosinophils and epithelium may also stimulate the 
secretion of many pro-inflammatory mediators.
PARs  are  suggested  to  play  an  important  role  in  inflammatory  and 
fibroproliferative  processes.  Pulmonary  fibrosis  is  characterized  by  rapid  fibroblast 
proliferation  and  overproduction  of  extracellular  matrix  proteins.  There  is  increasing 
evidence  that  especially  PAR-1  plays  a  significant  role  in  the  development  of 
proliferation  through  the  involvement  in  collagen  accumulation  and  expression  of 
profibrotic factors .
The epithelium participates in regulation of repair processes through the secretion 
of  extracellular  matrix  proteins.  Moreover,  the  epithelium  modulates  airway  smooth 
muscle  tone by production of  respective  mediators  and neurotransmitters.  It  has  been 
shown  in  vitro that  activation  of  PARs,  especially  PAR-2,  was  involved  in  these 
processes.  PAR-2  mediates  the  release  of  the  cytoprotective  and  relaxant  prostanoid 
prostaglandin (PG) E2, as well as the release of proinflammatory cytokines IL-6 and IL-8 
in human primary epithelial cells or epithelial cell lines  .  PAR-2 activation induces the 
production  of  MMP-9,  contributes  to  matrix  remodeling  .  Epithelial  PAR-2 has  been 
shown  to  induce  the  production  of  eotaxin  and  granulocyte  macrophage-colony 
stimulating  factor  (GM-CSF)  which  promotes  eosinophil  survival  and  recruitment  . 
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Furthermore, PAR-2 activation in airway epithelial cells increased neutrophil adhesion to 
the cells and caused changes in ion transport .
PAR-2 is an extensively studied receptor in the context of participation in lung 
pathophysiology.  However,  the  function  of  PAR-2  in  lung  biology  is  still  unclear. 
Activation of PAR-2 has been documented also  in vivo to induce both pro-  and anti-
inflammatory effects in animal models of inflammation, including studies with PAR-2-
deficient mice. Activation of PAR-2 caused protective bronchial relaxation in airways, 
inhibited the development  of eosinophilia and neutrophils influx into airways in LPS-
treated or ovalbumin-sensitized mouse .
On the contrary, PAR-2 was shown to be involved in airway hyperresponsiveness 
and eosinophil recruitment in allergen-challenged mice .
However, the action of activated PARs may depend on the type of stimuli applied, 
the  severity  of  pre-existing  inflammatory  status,  the  time  point  of  PAR  agonist 
administration, and finally, the types of PAR activated.
Some chronic lung diseases are frequently associated with changes in PAR protein 
expression as a result  of modulation of gene expression by a variety of inflammatory 
mediators.  For example,  asthmatic bronchial epithelium showed significant increase in 
PAR-2 level, compared to the non-asthmatic tissue . In preterm infants with prolonged 
chronic  lung  injury  PAR-2 immunoreactivity  was  significantly  higher  compared  with 
newborn infants without pulmonary pathology  .  Pulmonary fibrosis is accompanied by 
increased PAR-1 on alveolar macrophages and fibroproliferative foci . Increased levels of 
PAR-2 mRNA were also detected in lung fibroblasts from fibrotic tissues  .  In alveolar 
macrophages from smokers PAR-1 but not PAR-2 expression is changed compared to 
that in healthy subjects . In animal models, LPS-induced inflammation and viral infection 
enhanced PAR levels and their responsiveness  which is coupled to increased activation 
of COX and enhanced generation of bronchodilatory prostanoids .
However,  there  is  limited  information  about  particular  mediators  that  are 
responsible for the modulation of PAR expression on airway cells.  Studies on various 
cultured  human  airway  cells  showed  different  regulation  of  PAR  expression  by 
inflammatory  mediators.  In  pulmonary  artery  endothelial  cells,  TNF-α induced  the 
expression of PAR-2, but exerted no effect on the PAR-1 level . LPS and IL-1β were not 
able  to  modulate  PAR-1  and  PAR-2  expression  in  alveolar  macrophages  ,  while  in 
smooth muscle cells  IL-1β up-regulated PAR-2 . In pulmonary fibroblasts, profibrotic 
growth factors PDGF and TGF-β1 stimulated PAR-2 expression , the antifibrotic and 
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anti-inflammatory agent PGE2 was able to down-regulate the expression of PAR-1, -2, 
and  -3  .  Interestingly,  LPS  and  TNF-α in  bronchial  fibroblasts  up-regulated  PAR-2 
expression and induced functional expression of PAR-4 .
Nevertheless, there is still limited information concerning particular factors, which 
are responsible for alteration of PAR levels in lung epithelial cells. Therefore the question 
is  still  open,  which  factors  have  the  potential  ability  to  enhance  or  diminish  PAR-
mediated cellular  responses. Similarly,  the current understanding of the effect  of PAR 
agonists  and  the  contribution  to  pro-  or  anti-inflammatory  processes  during  airway 
disorders is incomplete. However, airway disorders, such as asthma and COPD, appear to 
be  partially  resistant  to  the  currently  available  pharmacological  agents.  Hence,  PARs 
might represent a useful subject for further investigation to provide a promising target for 
novel drugs for the treatment of various respiratory disorders .
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1.4 Aims of the project and outline of the present study.
The  main  focus  of  this  study  was  to  investigate  the  involvement  of  PARs  in 
inflammatory processes, which underlie airway disorders such as asthma.
In the human airways  all  four PARs (PAR-1 to -4) have  been  detected to  be widely 
distributed throughout the respiratory system  . The  respiratory epithelium has the  first 
contact with inhaled antigens acting not only as a physical barrier for inhaled infectious 
stimuli but actively participating in acute and chronic inflammatory reactions . Exposure 
of  epithelial  cells  to  deleterious  factors,  like  allergens,  bacteria,  pollutants,  and  to 
endogenous  proinflammatory  factors,  triggers  defence  mechanisms  by  modulation  of 
expression  and  secretion  of  different  bioactive  molecules  such  as  lipid  mediators, 
cytokines, extracellular matrix proteins. Among many factors that are employed in these 
epithelial responses are PARs. Recent  in vitro studies with cell lines clearly showed a 
strong impact of PAR activation in the lung epithelium on inflammatory responses and 
tissue  .  Although there are few studies giving clear evidence about the involvement of 
PARs in airway inflammation, their exact role in the pathophysiology of the respiratory 
system is still unclear. In our experimental study, investigations were conducted in vitro 
using  lung  epithelial  cell  lines  and  primary  cells.  Our  model  should  mimic  the 
inflammatory  state  in  asthma  and  show  the  complex  network  between  PARs,  their 
agonists and inflammatory stimuli. This study should contribute to a better understanding 
of the involvement of PARs in lung disorders. 
The outline of the present study is as follows (the points numbered 1) to 4) are indicated 
in Figure 1.3):
1) Determine whether inflammatory conditions induced by LPS, TNF-α, IL-8 and PGE2 
influence the PAR expression level.
2) Study if a persistent PAR activation and PAR activation combined with stimulation 
with LPS has influence on PAR expression.
3) Investigate if PAR activation stimulates production of cytokine TGF-β
4) Elucidate if PAR activation enhances IL-8 synthesis and whether LPS attenuates this 
process.
a) Evaluate the signaling pathway of PAR-induced IL-8 release. The focus is on three 
members of MAPKs, ERK1/2, JNK and p38.
i) Investigate  whether PAR-3 activation also triggers IL-8 release and study whether 
MAPKs belong to the signaling pathway of this process.
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Figure 1.3: Simplified scheme for the outline of the present study. 1) to 4) are explained in the 
text above.
The outline of this study is shown in the scheme in Fig. 1.3. The aim of this work 
was to study how PAR activation alone and in combination with bacterial endotoxin LPS 
control the PAR expression level and production of cytokines in airway epithelium. To 
achieve these aims, the changes in PAR expression in lung epithelial cells exposed to 
inflammatory mediators as well as during persistent activation of PARs were determined. 
Additionally, the PAR-triggered synthesis of inflammatory mediators, such as IL-8 and 
TGF-β1  was  explored.  Pharmacological  and  biochemical  tools,  such  as  the  use  of 
selective  inhibitors  and  western  blot,  were  applied  to  investigate  the  PAR-mediated 
MAPK activation. An additional issue was the role and signaling mechanism of PAR-3, 
the most elusive receptor among PARs. HEK cells transfected with PAR-3-GFP served as 
experimental model for this purpose.
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2 Materials and Methods
2.1 Materials
2.1.1 Chemicals and reagents
Chemicals Manufacturer
SLIGKV (H-Ser-Leu-Ile-Gly-Lys-Val-NH2)
GYPGQV (H-Gly-Tyr-Pro-Gly-Gln-Val-OH)
Bachem, Heidelberg, Germany
Dulbecco’s Modified Eagle’s Medium (DMEM)
Fetal calf serum (FCS)
HBSS (w/o Ca2+ and Mg2+)
Penicillin and Streptomycin
Biochrom, Berlin, Germany
HEPES Biomol, Hamburg, Germany
Bio-Rad protein assay dye reagent concentrate
Precision Plus Protein All Blue Standard
Bio-Rad Laboratories, München,
Germany
TFRGAP (H-Thr-Phe-Arg-Gly-Ala-Pro-NH2) Biosyntan, Berlin, Germany
Ponceau S solution (0.2% in acetic acid) 
Trypsin
Boehringer, Mannheim, Germany
PD 98059
SB203580
SP600125
U0126
TNF-α
IL-8
Calbiochem, La Jolla, CA, USA
Albumin Fraction V, Protease free Carl Roth, Karlsruhe, Germany
Magnet assisted transfection (MATra) IBA GmbH, Göttingen, Germany
NuPAGE® MOPS SDS Running Buffer (20x)
NuPAGE® Transfer Buffer (20x)
NuPAGE® LDS Sample Buffer (4x)
Invitrogen, Karlsruhe, Germany
SAGM™
SABM™ (supplements for SAGM)
Lonza, Verviers, Belgium
100 bp DNA ladders MBI  Fermentas,  St.  Leon-Rot, Germany
TRag  (Ala-pFluoro-Phe-Arg-Cha-HomoArg-Tyr-
NH2)
NeoMPS SA, Strasbourg, France
Accutase PAA, Coelbe, Germany
TEMED 
Triton-X-100
SERVA, Heidelberg, Germany
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Tween 20
Dimethyl sulfoxide (DMSO)
β-mercaptoethanol
Igepal CA630
Thrombin
SIGMA, Deisenhofer, Germany
Protease Inhibitor Cocktail Roche Molecular Biochemicals,Mannheim, Germany
siRNA Qiagen, Hilden, Germany
2.1.2 Kits
Type of kit Manufacturer
BigDye  Terminator  Cycle  Sequencing  Read 
reaction Kit
Applied Biosystem, Foster City, CA, 
USA)
RNeasy Mini Kit
Omniscript™ Reverse Transcription Kit
RNase-Free DNase
HotStarTaq™ Master Mix Kit
MiniElute PCR Purification Kit
Qiagen, Hilden, Germany
iScript™cDNA Synthesis kit
iQ™SYBR® Green Supermix
Bio-Rad
Supersignal West Pico kit Pierce, Rockford, IL, USA
Interleukin  8  [(h)IL-8]  Human,  Biotrak  ELISA 
System
Transforming  Growth  Factor-Beta1  (TGF-β1) 
Human, Biotrak ELISA System
Amersham  Biosciences  Freiburg, 
Germany
2.1.3 Antibodies
Antibody Manufacturer
mouse  monoclonal  anti-phospho-p44/42  MAPK 
(Thr202/Tyr204)
rabbit anti-p44/42 MAPK 
rabbit anti-phospho-JNK (Thr183/Tyr185)
rabbit anti-JNK
rabbit anti-phospho-p38 MAPK (Thr180/Tyr182)
rabbit anti-p38 MAPK
Cell Signaling Technology, Beverly, 
MA, USA
peroxidase-conjugated goat anti-mouse and
anti-rabbit IgG
Dianova, Hamburg, Germany
WEDE15 (anti PAR-1) Immunotech
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Alexa  Fluor®488  goat  anti-mouse  IgG  and  goat 
anti-rabbit IgG Molecular Probes
H-103 (anti PAR-3) Santa Cruz, Heidelberg, Germany
A5, polyclonal rabbit (anti PAR-2) gift  from  Dr.  M.  Hollenberg, Calgary, Canada
2.1.4 Laboratory instruments
Instrument Manufacturer
ABI PRISMTM 310 Genetic Analyzer Applied Biosystems Division, Foster 
City, CA, USA
Hybond C Amersham  Biosciences  Freiburg, 
Germany
Mighty Small II (for western blotting
electrophoresis)
Amersham  Pharmacia  Biotech 
Buckinghamshire, UK
Waterbath Bachofer, Reutlingen, Germany
T3 Thermocycler Biometra, Göttingen, Germany
Electrophoresis power supply 
Gel electrophoresis system
Semi-dry Transfer Cell
Mini PROTEAN II (Tankblot)
GS-800 Calibrated Densitometer
Molecular Imager Gel Doc XR System
Bio-Rad  Laboratories,  München, 
Germany
Thermomixer comfort Eppendorf
Biofuge A, 13 R, 3.2 RS (centrifuge)
LaminAir (clean bench)
Cell culture incubator
Heraeus, Hamburg, Germany
Refrigerator (4°C and –20°C) Liebherr, Hamburg, Germany
Millipore purification system and ultra-pure water 
system Millipore, Schwalbach, Germany
Innova 4230 Refrigerated incubator
shaker New  Brunswick  Scientific, Nürtingen, Germany
UV/visible Spectrophotometer Pharmacia Biotech
Gel-blotting-papers Schleicher  &  Schuell,  Dassel, 
Germany
pH Meter (pH526) WTW, Weilheim, Germany
2.1.5 Buffers and solvents
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2.1.5.1 Cell culture medium and solutions
 for A549 cells- DMEM: 3.7 g/L NaHCO3, 1.0 g/L D-glucose, 1.028 g/L N-Acetyl 
Lalanyl-L-glutamine, 10 % FCS, 100 U/ml Penicillin, 100 μg/ml Streptomycin
 for HEK-293 cells: DMEM/HAM’S F12 (1:1) with 2 mM Glutamine, 10 % FCS, 
100 U/ml Penicillin, 100 μg/ml Streptomycin
 for  HSAEC:  Small  Airway  epithelial  medium  (SABM)  supplemented  with 
growth  factors  (BPE,  hydrocortisone,  hEGF,  epinephrine,  insulin, 
trijodothyronine, transferrin, gentamicin/amphotericin-B, retinoic acid and BSA-
FAF)
 HBSS (Hanck’s balanced salt solution) without Ca2+ and Mg2+
 Accutase
 G418 Sulphate - stock: 500 mg/ml, working concentration: 500 μg/ ml
2.1.5.2 Buffers and solutions
 NaHBS  
145 mM Na Cl, 5.4 mM KCl, 1 mM MgCl2,  1.8 mM CaCl2, 25 mM glucose, 
20mM HEPES, pH 7.4 adjusted with Tris (hydroxymethyl) aminoethane
 1 x PBS  
137 mM NaCl, 2.6 mM KCl, 8.1 mM Na2PHO4, 1.4 mM KH2PO4, pH 7.4
 1 x TBS  
137 mM NaCl, 20 mMTris/HCl, pH 7.6
 1 x TBE  
89 mM Tris, 89 mM Boric acid, 2 mM Na2EDTA, pH 8.0
 10 x MOPS  
0.2 M MOPS, 10 mM Na2EDTA, 50 mM Na-Acetate, pH 7.0
 Ethidium bromide solution  : 10 mg/ml
 4 x Lysis buffer (RIPA buffer)  
50 mM Tris/HCl pH 7.4, 1 mM EDTA, 150 mM NaCl, 1% Igepal CA630, 0.25% 
Na-deoxycholate, 1mM Na3VO4, 1 mM NaF and Protease Inhibitor Cocktail
 60 % Acrylamide/Bis-100 ml  
Acrylamid 58.4 % (w/v), 1.6 % (w/v) N,N‘-Methylen-bisacrylamide
 Resolving buffer (SDS-PAGE-Laemmli)  
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750 mM Tris/HCl, pH 8.8
 Stacking buffer  
250 mM Tris/HCl, pH 6.8
 SDS solution  : 10% (w/v) SDS in H2O
 PER solution  : 10% (w/v) Ammoniumperoxodisulfat in H2O
 4 x Laemmli Sample buffer  
500 mM Tris/HCl, pH 6.8, 8% SDS (w/v), 40% Glycerol, 0.005% Bromphenol 
blue (w/v), 20 % (v/v) β-Mercaptoethanol
 5 x Laemmli Running buffer  
125 mM Tris, 960 mM Glycine, 0.5% SDS (w/v), pH 8.5
 1 x Transfer buffer (for Laemmli gels with NC membrane  )
25 mM Tris, 192 mM, Glycine, 20% (v/v) Methanol
 Membrane Stripping buffer  
62.5 mM Tris, pH 6.8, 100 mM β-Mercaptoethanol, 2% SDS
 PFA 4 %  
4 g PFA, 120 mM Na-Phosphate pH 7.4, 4 g saccharose
2.2 Methods
2.2.1 RNA isolation
Total RNA was isolated from the cells with the RNeasy Kit (Qiagen Hilden). The 
medium was aspirated from the culture dish (6 cm) and the cells were lysed with 600 µl 
RLT buffer. Cells were homogenized completely by pipetting and to this homogenized 
suspension 600 µl 70 % ethanol were added and mixed well by pipetting for precipitating 
the RNA. Then 600 µl of the sample were applied to a RNAeasy mini spin column sitting 
in a 2-ml collection tube, and centrifuged for 1 min at 10,000 rpm. 350 µl Buffer RW1 
were pipetted onto the RNeasy column, and centrifuged for 1 min at 10,000 rpm to wash 
lysate. Now On-column DNase digestion was performed to remove genomic DNA using 
the RNase-Free DNase Kit (Qiagen Hilden). 10 µl of DNase I stock solution were added 
(2.73 Kunitz units/µl) mixed in 70 ml Buffer RDD (DNase I incubation mix) directly onto 
the spin-column membrane and incubated at room temperature for 15 min. Next, 350 µl 
Buffer RW1 were pipetted into the column and centrifuged for 1 min at 10,000 rpm. The 
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RNeasy column was transferred into a new 2-ml collection tube and 500 µl Buffer RPE 
were pipetted onto the RNeasy column, centrifuged 1 min at 10,000 rpm and again 500 µl 
Buffer RPE were pipetted, centrifuged for 2 min at maximum speed to dry the RNeasy 
membrane. Finally, RNeasy column was transferred into a new 1.5 collection tube, and 30 
µl  RNeasy-free  water  were  pipetted  onto  RNeasy  membrane,  incubated  at  room 
temperature for 10 min, and then centrifuged for 1 min at 10,000 rpm to elute. Isolated 
RNAs were stored at -80°C.
2.2.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
1 μg of total RNA was reverse-transcribed using Omniscript Reverse Transcription 
kit (Qiagen, Hilden). RT reaction was set as follows:
RNA 1 μg
RT Buffer (10 x) 2 μl
dNTP mix (5 mM each) 2 μl
Oligo-dT primer (0.5 μg/μl) 2 μl
Omniscript Reverse Transcriptase (4 U/μl) 1 μl
H2O      ad 20 µl
RT was performed in T3 Thermocycler (Biometra). The reaction was incubated for 
1 h at 37°C, followed by 5 min at 95°C and then rapidly cooled at 4°C.
PCR reaction was done using the HotStarTaq™ Master Mix kit (Qiagen, Hilden). 
The reaction mixture was pipetted as follows:
cDNA 1 μl
HotStarTaq Master Mix 25 μl
5‘ primer (10 pmol/μl) 2 μl
3‘ primer (10 pmol/μl) 2 μl
H2O      ad 25 µl
The PCR reaction was made using the following program:
Lid temperature: 110°C
Preheating: On
Initial denaturation: 95°C 15 min
35 cycles: Denaturation: 94°C 30 sec
Annealing: variable   1 min 30 sec
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Extension: 72°C  1 min
Final extension: 72°C 10 min
Pause: 4°C
10 μl  of  reaction  used  for  gel  electrophoresis  to  check  for  the  presence  of  the 
expected gene product.
2.2.3 Reverse transcription and real-time PCR
To reverse transcribe the isolated total RNA from the cultured cells iScript™ cDNA 
synthesis kit (BioRad) was used. RT reaction mixture was as follows:
RNA template 1 µg
iScript Reverse Transcriptase 1 µl
5 x iScript Reaction Mix 4 µl
Nuclease-free water      ad 20 µl
RT was done in T3 Thermocycler (Biometra). The reaction mix was incubated for 5 
min at 25°C, followed by 30 min at 42 °C and 5 min at 85°C and subsequently cooled 
down to 4°C.
Real-time PCR is quantitative and qualitative online method, where the fluorescent 
emission  increases  when  SYBR  Green  dye  binds  to  the  double  stranded  DNA. 
Quantification  is  achieved  by  measuring  the  increase  in  fluorescence  during  the 
exponential phase of PCR and comparing the Ct  values of the samples of interest with 
control such as non-treated sample.  Both Ct  values are normalized to the hauskeeping 
gene GAPDH.
The specificity of the amplification was determined by generating melting curve 
profiles,  where  the  total  fluorescence  generated  by  SYBR  Green  binding  to  double-
stranded DNA as temperature changes is plotted in real time as a function of temperature. 
The melting temperature (Tm) of each product is defined as the temperature at which the 
corresponding peak maximum occurs. This analysis confirms the specificity of the chosen 
primers and reveals the presence of primer-dimers.
Real-time PCR was done using iQ™SYBR®Green Supermix (BioRad).The reaction 
mixture was pipetted as follows:
DNA template 1 µl
iQ SYBR Green Supermix        12.5 µl
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5’ Primer (10 µM) 1 µl
3’ Primer (10 µM) 1 µl
Sterile water      ad 25 µl
The  thermal  cycling  conditions  included denaturation  step  at  95°C  for  3  min, 
followed by 40 cycles at 94°C for 30 s, 60°C (PAR-1-3, IL-8, TGF-β1 and GAPDH) or 
64°C (PAR-4) for 60 s, 72°C for 1 min and the final melting curve program with ramping 
rate of 0.5°C/s from 60°C to 95°C.
Primers were based on human PAR-1, PAR-2, PAR-3, PAR-4, IL-8, TGF-β1 sequence. 
At the same time, samples without templates served as negative control.
Primers sequences were used as listed below:
Primer Sequence (5’→ 3’) Product length(bp)
PAR-1 f: CGCCTGCTTCAGTCTGTGCGGC 405
r: GGCCAGGTGCAGCATGTACACC
PAR-2 f: GCCATCCTGCTAGCAGCCTCTC 341
r: GATGACAGAGAGGAGGTCAGCC
PAR-3 f: TTGTCAGAGTGGCATGGAA 451
r: TGGCCCGGCACAGGACCTCTC
PAR-4 f: CAGCGTCTACGACGAGAGCGG 423
r: CACTGAGCCATACATGTGACCAT
IL-8 f: CTAGGACAAGAGCCAGGAAG 237
r: GTGTGGTCCACTCTCAATC
TGF-β1 f: CAGAAATACAGCAACAATTCCTGG 185
r: TTGCAGTGTGTTATCCCTGCTGTC
GAPDH f: TCCAAAATCAAGTGGGGCGATGCT 598
r: ACCACCTGGTGCTCAGTGTAGCCC
2.2.4 Agarose gel electrophoresis of DNA
To  confirm  the  quality  of  DNA  (PCR  product,  recombinant  plasmid  DNA, 
restriction analysis) 1% agarose (SIGMA) gel in 0.5 x TBE buffer was made. The gel was 
prestained with ethidium bromide (10 mg/ml) (SIGMA). DNA samples were prepared in 
6 x loading buffer (containing bromophenol blue dye) (MBI Fermentas). Gel was run in 
0.5 x TBE for 1 h at 80 V. GeneRuler 100 bp DNA Ladder (1 kb) (MBI Fermentas) was 
used. DNA bands were visualised under gel imaging system Molecular Imager Gel Doc 
XR System (Bio-Rad).
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2.2.5 Agarose gel electrophoresis of RNA
Quality  of  isolated  RNA was  checked  in  a  1% agarose/MOPS (N-Morpholino-3-
propansulphonic acid) gel. 0.1% DEPC-H2O (diethyl pyrocarbonate water) was used for 
all the solutions required for RNA gel including the sample preparation. 3% Hydrogen 
peroxide  (H2O2)  was  used  for  decontaminating  the  gel  assembly.  RNase-free  agarose 
(SIGMA) gel was made in 1 x MOPS buffer. Gel was pre-stained with ethidium bromide 
(10 mg/ml). 200 ng of RNA were used with 6 x Loading buffer. Gel was run in 1 x MOPS 
buffer for 1 h at 80 V. 18S and 28S RNA bands were visualised under gel imaging system 
Molecular Imager Gel Doc XR System (Bio-Rad)
2.2.6 DNA Sequencing
For sequencing reaction, either 100 ng of cleaned PCR DNA or 1 μg of recombinant 
plasmid DNA used with 2 μl of respective primer (10 µM) and 4 μl Big dye (contains 
DNA  polymerase,  fluorescent  dye-labelled  dNTPs,  buffer)  (Applied  Biosystems, 
Warrington, UK) were mixed with H2O to a final volume of 20 μl. The PCR conditions 
were:
Denaturation: 98°C for 2 min 
25 cycles: Denaturation: 96°C for 30 sec
Annealing: 55°C for 30 sec
Extension: 60°C for 4 min + 25 sec increament/cycle
Pause: 4°C
Sequencing PCR product was precipitated with sodium acetate and 70% ethanol and 
then resuspended in 25 µl of Template Suppression Reagent (TSR) buffer (ABI PRISM, 
Applied Biosystems Division, Foster City, CA, USA), denatured for 2 min at 95°C and 
then  kept  on  ice  for  2  min.  The  sequence  of  nucleotides  was  determined  by  a  ABI 
PRISMTM 310 Genetic Analyzer.
2.2.7 Quantification of nucleic acids
The quantity of isolated DNA and RNA was measured by the UV absorption ratio 
260  nm/280  nm  in  quartz  cuvette  (5.00  mm  thickness)  using  an  Ultrospec  2000 
UV/visible spectrophotometer (Pharmacia Biotech, Freiburg, Germany).
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2.2.8 Cloning
2.2.8.1 Generation of DNA insert by PCR
To  clone  a  particular  DNA  fragment  into  plasmid  vector  for  generating  a 
recombinant plasmid, PCR was done to amplify the full coding sequence of the gene. 
PAR-3 fragment was amplified with PCR (30 cycles: 30 sec at 94°C, 1 min at 51°C, 2 
min at 72°C and 10 min at 72°C) using a primer pair flanking the entire coding region 
(designed  on  published  human  PAR-3  sequence  in  the  Genbank;  Accession  number: 
U92971) and XhoI / HindIII restriction sites (underlined):
Sense: 5’-GTCATCCTCGAGAAAATGAAAGCCCTC-3’
Antisense: 5’-ATTTCACTAAAGTCTTTTTTGTAAGGTAAGC-3’
For cloning the full cDNA, the stop codon was mutated in the 3‘primer when cloned into 
a vector with a 3‘ detection tag. 1 µl of cDNA used for generating the required cDNA 
fragment with 2 µl of each primer (10 µM) using the Hotstar Taq Master Mix kit. The 
amplified PCR product (length 1140 bp) was loaded on the agarose, cut out from the gel, 
purified with Concert  Rapid Gel Extraction Kit (Gibco BRL) and digested with  XhoI 
/HindIII enzymes;  cleaned again to remove digestion buffer with Concert  Rapid PCR 
purification  kit  (Gibco  BRL),  quantified  and  ligated  into  pEGFP-N1  vector  (BD 
Biosciences Clontech, Germany). The DNA specificity was confirmed by sequencing.
2.2.8.2 Plasmid isolation from bacteria (mini-preparation)
Plasmid DNA from transformed bacteria  was  harvested  using the  Invisorb Spin 
Plasmid  Mini  Kit  (Invitek,  Berlin).  E.  coli  culture  (single  colony)  was  grown under 
appropriate antibiotic selection (here: kanamycin) in 3 ml LB media overnight at 37°C 
with  shaking  at  250 rpm.  Overnight  grown culture  was  centrifuged,  supernatant  was 
removed and pellet was resuspended in 200 μl of Solution I by vortexing. Next, 250 µl of 
Solution II were added, mixed carefully followed by application of 250 µl of Solution III 
mixing  and  centrifugation  step.  The  clarified  supernatant  was  decanted  into  the  Spin 
Filter; 200 μl of Binding Solution were added to the filled Spin Filter and centrifuged. 
750 μl  of  Wash Buffer PL were added,  centrifuged 2 times for  complete  removal  of 
residual  Wash Buffer  PL.  The Spin Filter  was  placed  into a  new Receiver  Tube and 
allowed the Spin Filter to air dry for 1 min for complete removal of ethanol in Wash 
Buffer.  Then  Elution  Buffer  was  added  directly  onto  the  membrane  of  Spin  Filter, 
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incubated at room temperature for 10 min. and finally centrifuged to recover the plasmid 
DNA. 
2.2.8.3 Plasmid DNA isolation from bacteria (midi-preparation)
Plasmid DNA from transformed bacteria was harvested using the HiSpeed Plasmid 
Midi Kit (Qiagen, Hilden). 50 ml of overnight grown transformed bacteria culture was 
centrifuged and bacterial pellet was resuspended in 4 ml of Buffer P1 containing RNase 
A. 4 ml of Buffer P2 were added, mixed and incubated at room temperature for 5 min. 
Then 4 ml of chilled Buffer P3 were added, mixed immediately but gently and poured 
into the barrel of the QIAfilter Midi Cartridge; incubated at room temperature for 10 min 
to allow precipitation of protein and genomic DNA at the top of the solution. In the mean 
time 4 ml of Buffer QBT were applied to equilibrated a Qiagen-tip 500 and allowed the 
column to empty by gravity flow. Then the cap was removed from the QIAfilter outlet 
nozzle and inserted the plunger into the cartridge and the cell lysate was filtered.  The 
Qiagen-tip was washed with 2 x 10 ml Buffer QC and placed in a fresh falcon tube. 
Plasmid DNA was eluted with 5 ml of Buffer QF, precipitated with 3.5 ml of Isopropanol 
(room temperature) and centrifuged immediately for 30 min at  5000 rpm. Supernatant 
was discarded and DNA pellet was washed with 2 ml of 70% ethanol and centrifuged for 
10 min at 5000 rpm. Again supernatant was discarded carefully and pellet was allowed to 
air-dry. Dried DNA pellet was redissolved in TE.
2.2.8.4 Isolation of DNA fragment from agarose gel
To isolate  DNA  fragment  (PCR product)  from agarose  gel,  Concert  Rapid  Gel 
Extraction Kit (Gibco BRL) was used. The area containing the DNA fragment was cut 
from the gel and 30 μl of Gel solubilization buffer (L1) for every 10 mg of gel was added. 
The gel slices were dissolved in buffer at 50°C and placed into a 2.0 ml cartridge. Next, 
centrifuged  for  1  min  at  maximum  speed;  discarded  the  flow-through;  500  μl  of 
Solubilization  buffer  (L1)  were  added  and  centrifuged  again;  the  flow-through  was 
discarded; 700 μl of Wash buffer (L2) (containing ethanol) were added and incubated for 
5 min at room temperature and finally centrifuged at maximum speed to remove residual 
wash buffer The cartridge was placed into a 1.5 ml recovery tube, pre-warmed TE buffer 
(70°C) was added, incubated for 10 min at room temperature and then centrifuged for 2 
min at 12,000 rpm.
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2.2.8.5 Cleaning of DNA fragment
DNA  fragments  after  PCR  amplification  and  restriction  digestion  were  cleaned 
using the Concert Rapid PCR Purification kit (Gibco BRL). The Binding Solution (H1) 
was added to the amplification reaction in ratio 4:1 and sample mix was applied into the 
cartridge in wash tube and centrifuged.  The next steps were: washing with 700 µl of 
Wash  Buffer  (H2)  (containing  ethanol)  and  multiple  centrifugations  to  remove  the 
residual wash buffer. Then the cartridge was placed into a 1.5 ml recovery tube; pre-
warmed TE buffer (70°C) was added, incubated for 10 min at room temperature and then 
centrifuged.
2.2.8.6 Hydrolysis of DNA with restriction endonucleases
DNA digestion was performed as follows:
DNA 5 µg
Enzyme 1 (10 U/µl) (Xho) 2 µl
Enzyme 2 (10 U/μl) (Hind III) 2 μl
Buffer (10x) (Y+/Tango)  2 x
H2O      ad 30 µl
Incubation time: 10-12 h at 37°C
After  restriction,  reaction  mix  was  purified  using  Concert  Rapid  PCR Extraction  kit 
(Gibco BRL). DNA was quantified as described above.
2.2.8.7 Ligation of plasmid and DNA
To generate recombinant plasmid, digested plasmid (pEGFP-N1) was ligated with 
the DNA insert (PAR-3) using the T4 DNA Ligase (Gibco BRL). 
Plasmid vector (EGFP-N1) 1 x
DNA insert (hPAR-3) 3 x
T4 DNA Ligase (1 U/µl) 1 μl
Ligase buffer (5x) 4 µl (1x)
H2O      ad 20 µl
Ligation was done in (T3) Thermocycler (Biometra) using following reaction conditions:
8 h 16°C
4 h 22°C
2 h 37°C
Pause  4°C
Ligation mixture was then used to transform bacteria to generate recombinant plasmid.
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2.2.8.8 Transformation of E. coli by heat-shock method (CaCl2 based)
For transformation of E. coli, DH5α strain was used. Cells were grown in 5 ml LB 
media overnight at 37°C with shaking at 250 rpm. 1 ml of overnight bacterial culture was 
then transferred to 100 ml of fresh LB media and continued to grow at 37°C with shaking 
till the cells reached their logarithmic phase i.e., OD 600= 0.3-0.4 (3-4 hours). Then the 
bacterial suspension was centrifuged at 6000 rpm in SS 34 Rotor in Sorvall centrifuge 
(pre-cooled) for 5 min at 4°C. Supernatant was discarded and cell pellet was resuspended 
in 10 ml of ice-cold 100 mM CaCl2 solution. The cell suspension was then incubated on 
ice in cold room (4°C) for 1 h and centrifuged for 5 min at 6000 rpm at 4 °C. Supernatant 
was discarded carefully and pellet was resuspended in 1 ml of ice-cold 100 mM CaCl2 
containing 30% glycerol. From this competent cell suspension aliquots of 200 µl were 
frozen in liquid nitrogen and stored at -80°C. 
To transform bacteria, 200 µl of CaCl2 competent cells were thawed on ice. To the 
cells 100 µl of cold TCM buffer were added and either 10-20 ng DNA of super-coiled 
plasmid or 20 µl of ligation mix. Next transformation reaction mix was incubated on ice 
for 20 min and then for 90 sec at 42°C (heat –shock) and then immediately incubated on 
ice for 1 min. 700 µl of LB media (pre-warmed at 37°C and without any antibiotic) were 
added to transformation mix and incubated for 30-60 min with shaking at 37°C. 100 µl of 
the  transformation  mixture  in  case  of  super-coiled  DNA plated  on  the LB-agar  plate 
containing suitable antibiotic. For ligation transformation, reaction mix was centrifuged 
briefly, supernatant discarded and pellet resuspended in the residual volume and plated on 
LB-agar containing suitable antibiotic. LB-agar plates incubated at 37°C.
2.2.9 Cell culture
The medium for culturing of cells was sterile and ready to use (Biochrom). Cells 
were incubated in cell culture incubator (Heraeus) in a humidified atmosphere of 95% air, 
5%  CO2 at  37°C.  A549  cells  (ATCC,  Wesel,  Germany)  were  cultured  in  DMEM 
(Dulbecco minimum essential medium) and HEK-293 cells (ATCC, Wesel, Germany) in 
DMEM/HAM’S  F12  (1:1)  supplemented  with  heat  inactivated  10%  FCS  (fetal  calf 
serum),  100 U/ml penicillin and 100 µg/ml streptomycin (Biochrom).  Primary human 
small  airway epithelial  cells  (HSAEC) (Cambrex,  Walkersville)  were grown in Small 
Airway Cell Basal Medium (SABM) supplemented with growth factors and antibiotics 
according to the manufacturer’s instructions.  HBE cells (provided by Prof. Dr. L. Pott, 
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Inst.  für  Physiologie,  Ruhr-Universität  Bochum,  Germany)  were  cultured  in  DMEM 
Ham’s F-12 (1:1) culture medium supplemented with gentamicin (50 µg/ml), kanamycin 
(50 µg/ml), ITS (10 µg/ml), hydrocortisone (1 µM), pituitary extract (3.75 µg/ml), EGF 
(25 ng/ml), T3 (30 nM), cholera toxin (10 ng/ml). Culture medium was changed every 2-3 
days. For cells passage A549, HSAE and HBE cells were washed with HBSS and then 
incubated with Accutase (PAA) for 3 min at 37°C to detach the cell from the dish bottom. 
Accutase  was  used  to  minimize  proteolytic  activation  of  PARs.  HEK-293  cells  were 
washed and resuspended with HBSS.
2.2.9.1 Lipotransfection
To express a fusion protein in mammalian expression system, recombinant plasmid 
was transfected into mammalian HEK-293 cell  lines using the Liposomal transfection 
reagent DOTAP (Roche Diagnostic). Plasmid DNA was isolated using the Invisorb mini 
plasmid kit (Invitek, Berlin) to obtain clean DNA. Cells were grown 60-80% confluent. In 
one tube 5 µg of DNA were diluted up to 50 μl with 20 mM HEPES, in another tube 30 μl 
DOTAP were mixed with 70 μl of 20 mM HEPES. Then DNA-HEPES solution was 
mixed with DOTAP-HEPES solution and incubated for 30 min at room temperature. The 
culture media was replaced with fresh medium without serum and antibiotic. Transfection 
mix containing DNA-DOTAP-HEPES was pipetted carefully into the dish. Cells were 
incubated in the transfection media for 12 h and then full medium containing serum and 
antibiotic was given to cells. The cells were visualised under the fluorescent microscope 
to confirm the expression of fusion protein in case of vector containing GFP tag (GFP 
fusion protein showed green fluorescence). To maintain stable transfected cells, selection 
antibiotic G418 Sulphate antibiotic (kanamycin and neomycin derivative) (Calbiochem) 
was applied.
2.2.9.2 Magnet assisted Transfection (MATra)
The  cells  were  transfected  with  siRNA using  Magnet  Assisted  Transfection  for 
adherent cells (MATra-A) reagent.  Cells  were grown 50-60% confluency on 21.5 cm2 
dish. 100 nM siRNA was diluted in 400 µl serum-free medium and mixed with 6 µl 
MATra-A Reagent and incubated at RT 20-30 min. Beads-mixture was applied to the 
cells  with  3.5 ml  medium without  serum.  The cells  were placed  immediately  on  the 
Magnet  Plate.  After  incubation  for  15  min,  Magnet  Plate  was  removed  and  medium 
changed to fresh one. 
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siRNA was synthesized by Qiagen (Hilden,  Germany).  The sequences of human 
PAR-1 siRNA were as follows: sense 5’-GGGACUGCUGGGAGGUUAA-3’; antisense 
5’-UUAACCUCCCAGCAGUCCC-3’  and  the  DNA  target  sequence: 
AAGGGACTGCTGGGAGGTTAA. As control siRNA served AllStars negative control 
siRNA.
2.2.9.3 Freezing and thawing of cells
Cells were frozen in DMSO and FCS for long storage when not required in the 
culture. Briefly, cells resuspended in 0.5 ml medium were frozen in cryo tube together 
with 50 µl DMSO (sterile) and 450 µl FCS (fetal  calf  serum) at  –20°C for 24h.Then 
shifted to –80°C for long storage or liquid nitrogen.
Cryo-preserved cells were quickly thawed in 37°C and cell suspension was dispensed into 
9  ml  of  complete  cell  culture  medium,  centrifuged  at  1000  rpm  for  3  min  at  room 
temperature.  Cell  pellet  was  resuspended  in  appropriate  medium and  transferred  into 
culture dish.
2.2.10 Protein chemistry
2.2.10.1Cell lysate
Serum-starved  cells  were treated  with  agonists  for  the respective  time needed. 
After stimulation, cells were rinsed with ice-cold phosphate-buffered saline (PBS) and 
lysed in 1 ml of modified RIPA Buffer. Cell lysate was gently rotated for 30 min at 4°C 
and centrifuged at 14,000 g for 15 min at 4°C. Supernatant was transferred into a fresh 
tube and pellet  discarded.  The  protein concentration  was determined by the Bradford 
method using bovine serum albumin as standard. Lysates were stored at –80°C.
2.2.10.2SDS-PAGE and immunoblotting
The  cell  lysate  was  prepared  as  described  above.  Samples  containing  equal 
amounts  of  protein  were  precipitated  with  ice  cold  acetone/methanol  solution  (1:1), 
denatured  in  Laemmli  sample  buffer  system,  loaded  to  SDS-PAGE  gels  and 
electrophoresed  for  1.30  min  at  120  V.  Samples  were  transferred  to  nitrocellulose 
membrane (0.2 µm) using semi-dry transfer system (Biorad) at constant voltage (10 V) 
and 200 mA for 60 min at room temperature. Membranes were stained for protein bands 
with 0.2% Ponceau S and then blocked in 3% BSA (bovine serum albumin) for 1 hour. 
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Membranes  were  incubated  overnight  at  4°C  with  phospho-p44/42  MAPK  (1:2000), 
phosho-JNK (1:2000), phosho-p38 MAPK (1:1000), washed three times in TBST-Tween 
(0.1%) (30 min total),  followed by incubation with horseradish peroxidase-conjugated 
anti-rabbit IgG or anti-mouse IgG (1:10,000) (Dianova, Hamburg) for 60 min at 25°C. 
Washing  step  was  repeated.  Bands  were  visualized  by  enhanced  chemiluminescence 
(Amersham Biosciences). To reprobe the membrane with second primary antibody the 
membranes were washed in TBS-Tween (0.1%), incubated in stripping buffer for 30 min 
at 55°C, washed extensively in TBS-Tween, blocked in 3% BSA and finally re-probed 
with  anti-p44/42  MAPK  (1:1000),  JNK  (1:1000),  p38  MAPK  (1:1000)  antibody. 
Washing step was repeated in TBS-Tween (0.1%) (30 min total), followed by incubation 
with  secondary  antibody  peroxidase-conjugated  anti-rabbit  IgG  or  anti-mouse  IgG 
(1:10,000) (Dianova, Hamburg) for 60 min. at 25°C. Quantification of the bands densities 
was carried out using a GS-800 calibrated densitometer and Quantity One software (Bio-
Rad). 
2.2.11 IL-8 protein determination
According to the manufacturer’s protocol, extracellular IL-8 protein was measured 
using IL-8 ELISA kit.  Briefly,  serum-starved  A549 cells  were stimulated with TRag, 
thrombin, PAR-2 AP alone or together with LPS for 24 h. HEK-293 used in our studies 
were treated with TRag or thrombin for 6 h. Then supernatants were collected for ELISA 
analysis.  The levels  of IL-8 were assayed at  an optical  density (OD) of 450 nm. For 
inhibitor studies, cells were pretreated with the inhibitors for 30 min prior to stimulation 
with agonists.
2.2.12 Immunocytochemistry
A549  cells  cultured  on  coverglass  were  washed  three  times  with  cold  PBS, 
incubated  with  primary  antibodies  against  PAR-1,  PAR-3  (20  µg/ml)  or  with  rabbit 
antiserum against PAR-2 (dilution 1:50) at 4°C for 1 h, washed three times in PBS and 
incubated with secondary antibodies conjugated to Alexa Fluor ® 488 (5-10 µg/ml) at 4°C 
for 1 h. Controls were made by omitting the primary antibodies. The cells were visualized 
with a LSM510 meta confocal laser scanning microscope (Carl Zeiss, Germany).
2.2.13 Cytosolic Ca2+ measurements
The cells grown on a coverslip were removed from culture dish and placed in 1 ml 
HEPES-buffered saline (HBS) for 30 min at 37°C, supplemented with 2 µM Fura-2-AM 
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(dissolved in DMSO). Loaded cells were transferred into a perfusion chamber with bath 
volume of about 0.2 ml and mounted on an inverted microscope (Zeiss, Axiovert 135). 
During the experiments  the cells  were continuously  superfused  with  buffer  heated  to 
37°C. Single cell fluorescence measurement of [Ca2+]i were performed using an imaging 
system  from  TILL  Photonics  GmbH.  Regions  of  interest  were  selected  before  the 
experiment started. Cells were excited alternatively at 340 nm and 380 nm for 30-100 ms 
at each wavelength with a rate of 0.33 Hz and the resultant emission was collected above 
510 nm. Images were stored on a personal computer and subsequently the changes in 
fluorescence ratio (F340/F380) were determined from selected regions of interest covering 
single cell.
The general principles of the measurement are based on the fact, that there are two 
forms of  Fura-2 in equilibrium solution:  Ca2+-free and Ca2+-binding Fura-2.  Although 
showing great similarity in emission spectra, they are different in their excitation spectra: 
if the Ca2+-Fura-2 complex is excited at 340 nm, the increasing of free Ca2+ concentration 
leads to an increased fluorescence at 510 nm. If the Ca2+-Fura-2 complex is excited at 380 
nm, increasing Ca2+ concentration leads to a decreased fluorescence at 510 nm. Therefore 
the ratio of fluorescence at the two wavelengths is directly related to [Ca2+]i.
2.2.14 Confocal imaging
Images  were taken on a  Zeiss  inverted  LSM510 meta  laser  scanning confocal 
microscope equipped with a Plan-Apochromat x63 objective. The GFP was excited using 
a 488 nm argon/krypton laser, and the emitted fluorescence was detected with a 505-530 
band pass filter. Images were processed with Zeiss confocal microscopy software, release 
3.2.
2.2.15 Analysis of fluorescence intensities
Fluorescence intensities of confocal images were analyzed using the Zeiss LSM 510meta 
software histo macro. Region of interests (closed free-shape curves surrounding ca. 60 
µm2) were set on the membrane of single cells and the average fluorescence intensity in 
the ROI was determined. The intensity values for the treated cells were normalized to 
untreated cells, which were set as 100%.
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2.2.16 Statistics
Statistical evaluation was done using the Student’s t-test, and ANOVA with Dunnett 
post test (compare all columns vs control column) and P<0.05 was considered significant. 
Data are given as mean values ± standard error of the mean (SEM).
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3 Results
3.1 Expression of the PARs in A549 cells and other lung epithelial cells.
3.1.1 Detection of PARs by RT-PCR.
The  gene  expression  of  four  subtypes  of  PARs  was  investigated  by  RT-PCR 
analysis using total RNA from A549 cells. Specific primers were used to amplify PAR-1, 
PAR-2, PAR-3 and PAR-4 mRNA. Simultaneous detection of GAPDH was used as an 
internal  control  of RT-PCR analysis.  The use of intron-flanking primers  excluded the 
possibility of genomic DNA amplification. As shown in Figure 3.1A, RT-PCR analysis 
revealed the presence of mRNA transcripts for PAR-1, PAR-2 and PAR-3 in A549 cells, 
giving PCR products of 405 bp, 341 bp and 451 bp long, respectively. A PCR fragment 
corresponding to PAR-4 (423 bp) was not detected. However, the possible appearance of 
the PAR-4 PCR signal was unambiguously confirmed using a plasmid containing the full 
length  DNA of  human PAR-4.  In  two other  airway epithelial  cells,  human bronchial 
epithelial  cells  (HBE)  and  human  small  airway  epithelial  cells  (HSAEC)  we  could 
determine the presence of PAR-1 and PAR-2 transcripts.
Figure 3.1: RT-PCR detection of PAR-1-4 in A549 cells in comparison with HBE cells 
and SAEC. A: RT-PCR analysis  of  PARs in  A549 cells.  Amplified  PCR product  was 
loaded on 1% agarose gel prestained with ethidium bromide (10 mg/ml). B: Quantification 
of PAR expression levels in A549, HBE and HSAE cells by real-time PCR. Measurements 
were normalized to the GAPDH mRNA level. The values given are means ± SE of three 
independent  measurements.  PAR expression  levels  are  expressed relative  to  the  PAR-1 
mRNA expression in A549 cells, which was chosen as a reference value of 1.
With the help of real-time PCR, the PAR mRNA level in all three epithelial cells, 
A549, HBE and HSAEC, could be determined (Fig. 3.1B). Quantification of the relative 
abundance of PARs showed the predominance of PAR-2 mRNA in all cells tested. In 
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A549, HBE cells and HSAEC PAR-2 expression levels were 7, 12 and 6 times higher 
than the respective PAR-1 transcript  level.  PAR-3 expression level in A549 cells  was 
comparable  to  the  PAR-1  transcript  level,  whereas  in  HBE and  HASEC  it  was  not 
significantly above the threshold value.  Similar to A549, also HBE cells  and HSAEC 
expressed  no  PAR-4.  Relative  amounts  of  PAR  transcripts  were  calculated  by 
normalization to the housekeeping gene GAPDH.
3.1.2 Detection and localization of PARs by immunocytochemistry.
To confirm the expression of PARs in airway epithelial cells on protein level and to 
determine  receptor  localization,  immunostainig  of  the  cells  was  performed  using 
antibodies against N-terminal parts of PAR-1, PAR-2 and PAR-3. Figure 3.2 shows the 
representative  pictures  for  PAR-1,  PAR-2,  and PAR-3 where  fluorescence  staining is 
clearly visible on the cell plasma membrane.
Figure  3.2: PAR  localization  in  human  airway  epithelial  cells. PAR  detection  and 
localization was determined by immunofluorescent staining. A549 cells (upper panel) and 
HSAEC (lower panel) were incubated with antibodies directed against PAR-1, PAR-2 and 
PAR-3. PAR localization was visualized by staining with secondary antibodies conjugated 
with the fluorescent dye Alexa Fluor  ® 488. Images are representative for three different 
experiments.
Immunostaining  with  antibodies  against  N-terminal  parts  of  PAR-1,  PAR-2 and 
PAR-3 confirmed the presence of these three PAR proteins on the plasma membrane of 
A549
HSAEC
PAR-1                         PAR-2                          PAR-3
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A549 cells (Fig. 3.2, upper panels) and PAR-1 and PAR-2 in HSAEC (Fig. 3.2, lower 
panels),  and in HBE cells (data not shown). The fluorescence staining for PAR-1 was 
always weaker than that for PAR-2 and was hardly detectable on some portions of the 
cells. This is consistent with the low transcript level of PAR-1. The negative controls in 
this study, where we used only secondary antibody, yielded no detectable labeling (data 
not shown).
3.1.3 PAR agonist-mediated mobilization of Ca2+ in A549 cells.
PARs are  G protein-coupled receptors  and hence mobilize  intracellular  Ca2+.  To 
provide evidence for functional expression of PARs on A549 cells we examined the effect 
of PAR agonists on intracellular calcium concentration, [Ca2+]i. As shown in Figure 3.3, 
short-term application  of  the  synthetic  PAR-1-activating  peptide,  TRag  (Ala-pFluoro-
Phe-Arg-Cha-HomoArg-Tyr-NH2) (5 µM) or the PAR-1 and PAR-3 agonist thrombin (5 
U/ml) induced a comparable transient increase of [Ca2+]i in the A549 cell line (Fig. 3.3A, 
C) and primary HSAEC (Fig. 3.3B, D), and comparably in the HBE cell line (data not 
shown). All three cell lines demonstrated high heterogeneity in terms of Ca2+ response to 
TRag even within the same experiment. The PAR-1 activating peptide induced a [Ca2+]i 
elevation  only  in  a  small  number  of  cells  while  the  majority  of  the  cells  remained 
unresponsive. Moreover, only at concentrations of 5 µM and higher, TRag produced a 
Ca2+ response in epithelial cells. This can be due to the low density of PAR-1 on the cell 
surface  that  was  shown  immunocytochemically  (Fig.  3.2)  and  which  might  be  not 
sufficient for stable Ca2+ signaling. Similarly to TRag, thrombin induced a heterogeneous 
Ca2+ response in HSAEC, whereas in A549 cells an elevation of [Ca2+]i was observed for 
all cells. This may be due, in A549 cells, to the expression of another thrombin receptor, 
PAR-3.  A  transient  elevation  of  [Ca2+]i was  achieved  also  after  application  of  the 
synthetic  PAR-2-activating  peptide  SLIGKV (200  µM)  (Fig.  3.3E,  F).  In  contrast  to 
PAR-1 AP, PAR-2 AP always induced stable Ca2+ responses in all epithelial cells tested. 
This reflects  the high level  of PAR-2 expression.  Application of the synthetic PAR-3 
peptide (TRFGAP-NH2) and PAR-4 peptide (GYPGQV) did not induce any effect in all 
three cell line even when used up to 500 µM (data not shown). However, it is important to 
note, that the effectiveness and specificity of the PAR-3 peptide is still  controversial . 
Taken together, we can conclude that PAR-1 and PAR-2 are functionally expressed in 
lung  epithelial  cell  lines  A549,  HBE  and  primary  HSAEC  and  PAR-2  is  the  main 
functional receptor in terms of Ca2+ signaling.
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Figure  3.3: Rise  of  intracellular  calcium  concentration  ([Ca2+]i)  in  human  airway 
epithelial cells induced by PAR agonists. Ca2+ responses elicited in A549 cells (A, C, E) 
and primary HSAEC (B, D, F) by the PAR agonists TRag, thrombin and PAR-2 AP. The 
fura-2 AM-loaded cells were exposed to 5 µM TRag, 5 U/ml thrombin or 200 µM PAR-2 
AP for 60 s, as shown by the horizontal bar.  The increase in [Ca2+]i is indicated by the 
change  in  the  measured  fluorescence  ratio  (F340/F380 nm).  The  traces  give  responses  of 
individual  cells  from one  experiment.  The  pictures  are  representative  for  at  least  three 
different experiments.
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3.2 Evaluation of PARs activation by trypsin isoforms in airway epithelial cells.
Previous  results  have  described  that  bovine  pancreatic  trypsin  caused  [Ca2+]i 
signaling in particular through the activation of PAR-2 in the epithelial cell lines . To 
determine  whether  human  trypsin  isoforms  could  also  activate  PAR-2,  we  tested  the 
ability of all three human trypsin isoforms, cationic, anionic trypsin and mesotrypsin, to 
cause  [Ca2+]i elevation  in  A549  lung  epithelial  cells.  The  cells  were  exposed  to 
recombinant trypsins for 60 s, which is sufficient time to produce the peak amplitude of 
Ca2+ responses for any given concentration of PAR agonists (as it was shown in Fig. 3.3).
The  purity  and  homogeneity  of  the  samples  of  recombinant  human  cationic 
trypsinogen (PRSS1), anionic trypsinogen (PRSS2) and mesotrypsinogen was confirmed 
as described before  .  The activity of the three trypsin isoforms was comparable when 
measured  on  turnover  of  the  fluorogenic  substrate  Boc-Glu-Ala-Arg-7-amido-4-
methylcoumarin. 
Figure 3.4 represents typical Ca2+ responses in A549 cells elicited by the same 
concentration (10 nM) of cationic trypsin (A), anionic trypsin (B) and mesotrypsin (C). 
These data are also representative for HBE cells (data not shown). These cells produced 
similar Ca2+ responses as the A549 cells.  Cationic and anionic trypsins caused [Ca2+]i 
elevation comparable to that produced by the application of commercial bovine trypsin, 
whereas  mesotrypsin  was  completely  ineffective.  Concentrations  up  to 400  nM 
mesotrypsin which is approximately 4-fold higher than the saturating concentration of 
trypsin for PAR-2 activation in human lung epithelial cells  were not able to elicit [Ca2+]i 
signaling. Additional  pulses  of  commercial  bovine  trypsin,  given  3  min  after  the 
mesotrypsin  applications  were  applied  to  find  out  whether  mesotrypsin  is  able  to 
influence the PAR responsiveness. The amplitude of the subsequent Ca2+ responses to 
bovine trypsin was not affected, suggesting that mesotrypsin was ineffective with respect 
to both PAR activation and PAR receptor disabling. Thus, it is possible that mesotrypsin, 
in contrast to cationic and anionic trypsin isoforms, cannot activate or disable PARs in 
human epithelial cells.
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Figure 3.4: Rise of intracellular calcium concentration ([Ca2+]i) in A549 cells induced 
by different isoforms of human recombinant trypsin. The fura-2 AM-loaded cells were 
exposed to 10 nM cationic trypsin (PRSS1) (A), 10 nM anionic trypsin (PRSS2) (B), 10 nM 
mesotrypsin (PRSS3) followed by 10 nM bovine trypsin (C) for 60 s, as indicated by the 
horizontal line, and the changes in fluorescence (ΔF340 nm /F380 nm) were detected. The traces 
are  the  mean  of  minimally  25  single  cells  measured  in  one  experiment  and  are 
representative for at least three different experiments.
HBE cells were used to characterize the ability of the respective trypsin isoforms 
to  induce  Ca2+ responses.  The  data  for  the concentration  dependence  of  the response 
amplitude  (peak  change of  the ratio above basal  level)  allowed to determine  that  the 
effectiveness of cationic trypsin was similar to that of commercial bovine trypsin. The 
latter  had already been characterized  before  in  HBE cells  .  As  shown in Figure 3.5, 
anionic  trypsin  was  20-30%  less  effective  than  cationic  one.  Analysis  of  the 
concentration-effect curves revealed similar parameters for both trypsin isoforms, an EC50 
value of about 5 nM and 6 nM for cationic and anionic trypsin, respectively. The response 
maximum was obtained at about 10 nM.
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Figure  3.5:  Concentration-effect  curves  for  recombinant  human  trypsin  isoforms 
inducing [Ca2+]i rise in human HBE cells. The fura-2-AM loaded cells were stimulated 
with  varying  concentrations  of  the  cationic  or  anionic  trypsin  and  the  change  in 
fluorescence  (ΔF340 nm  /F380 nm) was detected. Data represent the mean ±s.e. from 70 single 
cells obtained in at least three separate experiments. SE from a minimum of 25 single cells 
measured in at least 3 different experiments (in some cases the error bars are smaller in size 
than the symbols used).
The next aim was to prove that the recombinant human trypsin isoforms cause 
[Ca2+]i signaling in particular through the activation of PAR-2 in the epithelial cells. This 
was established in the epithelial cell lines with bovine pancreatic trypsin before . For this 
purpose  we tested whether the Ca2+ responses produced by the trypsin isoforms were 
influenced  by  PAR-2  desensitization.  We  achieve  this  by  PAR-2  activation  with  its 
specific  agonist,  PAR-2  AP.  The  results  are  shown  in  Figure  3.6.  The  quantitative 
analysis of the responses produced by cationic and anionic trypsin is shown by the two 
first  grey bars,  marked as “contr”,  with the respective  patterns.  The responses  due to 
stimulation with both trypsin isoforms as a second pulse, following the exposure of the 
cells to PAR-2 AP (response marked as black bars) is presented as a group of three bars in 
the middle and on the right. The cytosolic Ca2+  release produced by cationic or anionic 
trypsins  after  treatment  of the HBE cells  with high concentrations  of PAR-2 AP was 
significantly  decreased  as  compared  to  the  control  measurement.  After  PAR-2 
desensitization with 600 µM PAR-2 AP, the effect of both cationic and anionic trypsins 
was reduced up to 4-5 times. 
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These data  confirm that  cationic  and anionic  trypsin cause [Ca2+]i elevation in 
human lung epithelial cells mainly through PAR-2 activation.
Figure  3.6:  Effect  of  PAR-2 desensitization  induced  by  PAR2-AP on  cationic  and 
anionic trypsin isoforms-mediated Ca2+ responses in HBE cells. Control cells were not 
exposed to the peptide before the protease addition (left group of columns). HBE cells were 
treated with 400 or 600 µM PAR-2 AP (black bars) followed by the application of 10 nM of 
cationic or anionic trypsins. The amplitude values of the Ca2+ responses are given as means 
± SE from a minimum of 50 single cells measured in at least 3 different experiments.
3.3 Modulation of PAR expression and synthesis of cytokines by exposure of the cells 
to inflammatory mediators and / or PAR activation.
3.3.1 Effect of inflammatory mediators on the expression of PARs, IL-8 and TGF-
β1 in A549 cells.
To  examine  the  influence  of  different  inflammatory  mediators  on  the  PAR 
expression, the cells were incubated with proinflammatory agents LPS, TNF-α, and IL-8 
for 4 h and 24 h and then the mRNA level for each PAR was determined by real-time 
PCR analysis. As it is shown in Figure 3.7A, exposure of A549 cells to LPS (10 µg/ml) 
for  4  h  induced  significant  up-regulation  of  PAR-2  expression,  about  1.8-fold  above 
control (P<0.01). After 24 h of incubation the value returned to basal level. LPS did not 
influence PAR-1 and PAR-3 expression levels. TNF-α (20 ng/ml) induced up-regulation 
of PAR-1, PAR-2 and PAR-3 transcript levels only after the long-term stimulation of 24 h 
(1.6, 1.7, and 1.4 fold, respectively (Fig. 3.7B). Unlike LPS and TNF-α, IL-8 (2 ng/ml) 
induced only slight down-regulation of the three PARs by 25-30% with a  significant 
∆F
34
0 
/F
38
0
0.0
0.1
0.2
0.3
0.4
0.5
0.6
PAR2-AP
Cationic trypsin (PRSS1)
Anionic trypsin (PRSS2)
                  contr             desens            desens
PAR-2AP                     +                      +
   (µM)                        (400 µM)         (600 µM)
45
Results
effect for PAR-2 mRNA. This effect developed only after long-term stimulation for 24 h 
and appeared only when the low concentration (2 ng/ml) was tested (Fig. 3.7C). Higher 
concentrations (20 and 200 ng/ml) exhibited no effect (data not shown).
Figure 3.7: Effect of LPS, TNF-α and IL-8 on the expression of PARs, IL-8 and TGF-
β1 in A549 epithelial cells. Changes in PAR mRNA levels after incubation with 10 µg/ml 
LPS (A), 20 ng/ml TNF-α (B) or 2 ng/ml IL-8 (C) as well as corresponding changes in IL-8 
and  TGF-β1  mRNA  levels  (D)  for  the  time  periods  indicated  below  the  graphs  were 
estimated  by  real-time  PCR.  Modulation  of  mRNA  expression  was  calculated  using 
GAPDH as  a  reference  gene.  Data  are  means  ±  SE of  three  independent  experiments. 
Dotted  line  at  “1” indicates  control  level.  Grey bars  point  on used agonist.  ***p<0.001, 
**p<0.01,  *p<0.05 as compared with the untreated cells.
To ascertain the action of these inflammatory mediators, we also measured changes 
in the expression of the proinflammatory chemokine IL-8 and the immunomodulatory 
agent  TGF-β1  (Fig.  3.7D).  TNF-α  induced  a  robust  increase  (200-fold)  of  the  IL-8 
transcript level as early as 4 h after addition of the agent, and this effect was retained up 
to 24 h. This finding is consistent with a previous report  .  Compared to TNF-α, LPS 
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induced smaller, but significant up-regulation of IL-8 expression (7.5 fold), whereas IL-8 
did not affect the expression of its own gene. Expression of TGF-β1 was not changed 
upon LPS stimulation  of  A549 cells,  while  TNF-α induced a  significant  (2-fold)  up-
regulation. IL-8 had no effect at 4 h and slightly down-regulated the TGF-β1 expression 
after 24 h of stimulation. 
When A549 cells were stimulated with the anti-inflammatory agent PGE2 (500 nM), 
a biphasic effect of PGE2 on PAR expression levels could be observed during the period 
of incubation (Fig. 3.8A).
Figure  3.8:  Effect  of  PGE2  on the  expression  of  PARs,  IL-8  and  TGF-β1 in  A549 
epithelial cells. Changes in PAR, IL-8 and TGF-β1 mRNA levels after incubation with 500 
nM PGE2 after 6, 10 and 16 hours was estimated by real-time PCR. Modulation of mRNA 
expression was calculated using GAPDH as a reference gene. Data are means ± SE of three 
independent experiments.  Dotted line at “1” indicates control level. Grey bars below the 
graphs indicate the agonist used. ***p<0.001, **p<0.01, as compared with the untreated cells. 
PAR-1 to -3 mRNA levels were down-regulated significantly by 40-50% after 10 h of 
incubation  with  PGE2,  while  16 h  stimulation  with  this  prostanoid  caused  significant 
(P<0.01) up-regulation of the PAR-2 mRNA level (1.8-fold). Short-term (3 h) and long-
term (24 h) stimulations  with PGE2 did  not alter  the PAR expression levels  (data  no 
shown). PGE2 did not affect the expression level of IL-8 during the complete period of 
incubation, whereas it slightly increased the TGF-β1 mRNA level, but only after 16 h of 
incubation (Fig. 3.8B).
3.3.2 Modulation  of  PAR,  IL-8  and  TGF-β1  expression  by  continuous  PAR 
activation in A549 cells.
Next, the effect of continuous PAR activation on PAR expression was examined. 
Stimulation with the PAR-1 agonist TRag (5 µM) for 4 h did not affect PAR-1 expression 
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but slightly up-regulated the PAR-2 level by 1.5-fold (Fig. 3.9A). Longer stimulation (24 
h) resulted in significant up-regulation of PAR-1 and PAR-2 mRNA, by 1.5- and 2-fold, 
respectively (P<0.01). Surprisingly, thrombin (5 U/ml), also a PAR-1 agonist, reproduced 
the effect of TRag only in case of PAR-2 after 24 h of incubation.
Figure 3.9: Modulation of PAR expression by PAR agonists in A549 cells. Changes in 
PAR mRNA level after treatment with PAR-1 agonists (5 µM TRag or 5 U/ml thrombin) 
(A) or with PAR-2 agonists (200 µM PAR-2 AP or 10 nM trypsin) (B) for times indicated 
were estimated by real-time PCR. Modulation of mRNA expression was calculated using 
GAPDH as  a  reference  gene.  Data  are  means  ±  SE of  three  independent  experiments. 
Dotted  line  at  “1” indicates  control  level.  Grey  bars  point  on  used  agonist.  ***p<0.001, 
**p<0.01, *p<0.05 as compared with the untreated cells. 
Activation of PAR-2 by PAR-2 AP for 4 h up-regulated PAR-1 and PAR-2 mRNA 
levels (Fig. 3.9B). The PAR-2 level was influenced more than that of PAR-1 (2.8 vs. 1.8 
fold, P<0.01). After 24 h of stimulation with PAR-2 AP, the transcript level for PAR-1 
remained elevated while that of PAR-2 tended to decline, but was still significantly higher 
than the control level (P<0.05). Trypsin induced only PAR-1 mRNA up-regulation after 
24 h of stimulation. All the agonists tested did not affect the PAR-3 expression level.
Taken together, in A549 cells, PAR-2 is the most strongly affected receptor in 
terms of regulation of its expression after activation of the various PARs. To support this 
observation,  the studies  of PAR-2 mRNA expression changes were extended to  HBE 
cells. As shown in Figure 3.10A, like in A549 cells, stimulation of HBE cells with the 
PAR-1 agonists  TRag and thrombin induced slight  up-regulation of  the PAR-2 level. 
Activation of PAR-2 using activating peptide significantly increased its own mRNA level 
after 4 h as well as after 24 h of exposure (Fig. 3.10B).
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Figure 3.10: Modulation of PAR-2 expression by PAR agonists in HBE cells. Changes 
in PAR mRNA level after treatment with PAR-1 agonists (5 µM TRag or 5 U/ml thrombin) 
(A) or with PAR-2 agonists (200 µM PAR-2 AP or 10 nM trypsin) (B) for times indicated 
were estimated by real-time PCR. Modulation of mRNA expression was calculated using 
GAPDH as  a  reference  gene.  Data  are  means  ±  SE of  three  independent  experiments. 
Dotted  line  at  “1” indicates  control  level.  Grey bars  point  on used agonist.  ***p<0.001, 
**p<0.01, *p<0.05 as compared with the untreated cells. 
In HSAEC, stimulation with TRag and thrombin did not exhibit significant effects 
on PAR mRNA level. Only exposure of the cells to PAR-2 AP induced up-regulation of 
PAR-2 mRNA level up to 1.7-fold (data not shown).
In summary, PAR-1 and PAR-2 activation on epithelial cells induced up-regulation 
of PAR-1 and more prominently PAR-2 expression. The PAR-2 activator showed higher 
effects than the PAR-1 activators.
3.3.3 The influence  of  concomitant  stimulation  with  PAR agonists  and  LPS on 
PAR expression in A549 cells.
Next, we studied how PAR expression might be affected by simultaneous treatment 
of  A549  cells  with  both,  the  inflammatory  mediator  LPS  and  PAR  agonists.  This 
combination  of  stimuli  may  reflect  the  pathological  situation  in  vivo when  both, 
proinflammatory  mediators,  e.g.  from  pathogens,  and  PAR-activating  proteases  are 
present in the airways at elevated levels. Incubation of A549 cells with LPS together with 
the PAR-1 agonist (TRag) for 4 and 24 h diminished or completely abolished the up-
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regulation of PAR-1 and PAR-2 (Fig. 3.11A, B), induced by the stimulation only with 
TRag, as shown above in Figure 3.10A.
Addition of thrombin together with LPS caused an effect similar to that induced by 
TRag together with LPS. Application of PAR-2 AP in combination with LPS completely 
abolished the up-regulation of PAR-1, which was induced when PAR-2 AP was applied 
alone (Fig. 3.11A).
Figure 3.11: The influence of simultaneous action of PAR agonists and LPS on PAR 
expression. Changes in PAR-1 (A), PAR-2 (B), and PAR-3 (C) mRNA after simultaneous 
stimulation with PAR agonist together with LPS were estimated by real-time PCR. The 
cells were incubated with LPS (10 µg/ml) simultaneously with TRag (5 µM), thrombin (5 
U/ml)  or  PAR-2 AP (200 µM) for the  different  times  indicated.  Modulation  of mRNA 
expression was calculated using GAPDH as a reference gene. Data are means ± SE of three 
independent experiments. Dotted line at “1” indicates control level.  Grey bars below the 
graphs  indicate  the  agonist  used.  ***p<0.001,  **p<0.01,   *p<0.05  as  compared  with  the 
untreated cells.
However, differently to PAR-1, the PAR-2 expression level after 4 h of concomitant 
stimulation  of  the  cells  with  LPS  and  PAR-2  AP  remained  elevated  (Fig.  3.11B). 
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Interestingly, prolonged (24 h) simultaneous treatment of A549 cells with LPS and the 
PAR agonists resulted in down-regulation of the PAR-3 mRNA level. The decrease was 
up to 2 times (P<0.001 for the combination of PAR-2-AP and LPS) (Fig. 3.11C).
We attempted to measure changes of PAR-2 protein level on the cell surface using 
immunocytochemical analysis. We stimulated epithelial cells with either LPS or PAR-2 
AP or with their combination for 4 h and waited for an additional 2 h incubation period 
after withdrawal of the stimuli. Then we observed an increase by 30% in the fluorescence 
signal  intensity  of the PAR-2 (data  not shown).  These results  correlate  with the data 
obtained by RT-PCR shown in Fig. 3.7A and 3.11B.
These data again underpin the importance of PAR-2. The most affected receptor, in 
terms  of  regulation  of  its  expression  after  activation  of  the  PARs  and  simultaneous 
exposure to the inflammatory mediator LPS, is PAR-2.
3.3.4 Modulation of IL-8 synthesis in airway epithelial cells by PAR activation with 
simultaneous exposure to LPS.
In parallel  with the determination of changes in PAR expression after  persistent 
PAR activation in A549 cells, we tested the ability of the PAR agonists to induce the 
synthesis  of  IL-8.  The  exposure  of  the  A549  cells  to  the  specific  PAR-1-activating 
peptide TRag did not change the IL-8 mRNA level significantly. However, stimulation 
with thrombin up-regulated the IL-8 mRNA level in A549 cells after 4 h up to 3.5 fold 
(P<0.01). This effect persisted for 24 h of incubation (P<0.001). Activation of PAR-2 by 
the  specific  peptide  PAR-2 AP increased  the  IL-8 mRNA level  after  4  h  by 14-fold 
(P<0.01). After 24 h stimulation the effect was attenuated but still significant (2.4-fold 
(P<0.01)) (Fig. 3.12A). To verify the PAR agonist-induced IL-8 up-regulation on protein 
level, the secreted IL-8 in cell culture supernatants was determined by ELISA. Similar to 
the mRNA level described above, IL-8 secretion was induced by PAR agonists in A549 
cells (Fig. 3.12B). However, when the cells were stimulated with TRag we could detect 
almost no change in IL-8 protein level after 4 h and 24 h of stimulation, compared to 
untreated  cells.  Only  thrombin  induced  approx.  3-fold  increase  in  IL-8  secretion.  As 
expected,  PAR-2  AP  stimulation  resulted  in  increase  11-  and  20-times  of  IL-8 
concentration  in  the  culture  medium  after  4  h  and  24  h  of  incubation,  respectively 
(P<0.01). The most potent agent to stimulate the IL-8 transcription was PAR-2 AP.
We also  investigated  the  effect  of  simultaneous  treatment  with  LPS and PAR 
agonists on the expression and synthesis of IL-8. LPS alone induced significant 7.6- and 
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4- fold up-regulation of the chemokine expression after 4 and 24 hours, respectively. The 
IL-8 expression was enhanced up to 30 times (P<0.01) after 4 h of stimulation with LPS 
together with PAR-1 and -2 agonists (TRag, thrombin, PAR-2 AP). However, after 24 h 
of co-stimulation with LPS and PAR agonists,  the expression level  of IL-8 decreased 
significantly  compared  to  the  short-term  stimulation  for  4  h,  but  still  remained 
significantly higher than the control level, as shown in Figure 3.12A.
Figure 3.12: Induction of IL-8 synthesis by PAR agonists alone or in combination with LPS 
in A549 cells. Changes in IL-8 mRNA level after 4 and 24 hours of incubation were estimated by 
real-time PCR Modulation of mRNA expression was calculated using GAPDH as a reference 
gene (A). IL-8 secreted into the medium was quantified by ELISA (B). The cells were incubated 
with TRag (5 µM), thrombin (5 U/ml) or PAR-2 AP (200 µM) alone or together with LPS (10 µg/
ml). Data are means ± SE of three independent experiments. Dotted line at “1” indicates control 
level. Grey bar below the graphs indicate applied LPS. ***p<0.001, **p<0.01, *p<0.05 as compared 
with the untreated cells.  ###p<0.001,  #p<0.05 as compared with the cells  treated with only one 
agonist.
The potentiation of the IL-8 expression after the challenge of the A549 cells with 
LPS together with thrombin and PAR-2 agonist also led to amplified IL-8 secretion (Fig. 
3.12B).  The  effects  of  the  agonists  on  the  mRNA  level  described  above  were  seen 
similarly on protein level. Concomitant exposure of the cells to thrombin or PAR-2 AP 
together with LPS induced a 16- or 27-times elevated amount of IL-8 release. Thus, in 
A549 cells we observed an amplifying effect of PAR-2 AP or thrombin together with LPS 
on IL-8 synthesis, compared to the effects of each stimulus alone.
We confirmed the modulation of IL-8 production by PAR agonists using primary 
HSAEC.  Stimulation  of  these  cells  with  the  PAR-1-activating  peptide  TRag  did  not 
induce IL-8 mRNA synthesis and protein release from these cells (Fig. 3.13A, B). This 
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was detected by real-time PCR and ELISA, respectively. Thus, consistently in both lung 
epithelial cell lines, A549 and HSAEC, PAR-1 was not able to induce IL-8 production. 
Stimulation of HSAEC with thrombin resulted in an increase of the IL-8 transcript level 
and in protein release (Fig. 3.13A, B).
Figure 3.13: Induction of IL-8 synthesis by PAR agonists alone or in combination with LPS 
in HSAEC. Changes in IL-8 mRNA level after 4 and 24 hours of incubation were estimated by 
real-time PCR Modulation of mRNA expression was calculated using GAPDH as a reference 
gene (A). IL-8 secreted into the medium was quantified by ELISA (B). The cells were incubated 
with TRag (5 µM), thrombin (5 U/ml) or PAR-2 AP (200 µM) alone or together with LPS (10 µg/
ml). Data are means ± SE of three independent experiments. Dotted line at “1” indicates control 
level. Grey bar below the graphs indicate applied LPS. ***p<0.001, **p<0.01, *p<0.05 as compared 
with the untreated cells. #p<0.05 as compared with the cells treated with only one agonist. 
In HSAEC the IL-8 expression was increased by 1.6 fold after 4 h stimulation, and 
was further significantly  increased after  24 h stimulation (2.2 fold)  (Fig.  3.13A). The 
delayed  response  of  HSAEC  to  PAR-2  agonist  might  be  a  characteristic  feature  of 
primary cells,  which was also documented in another work . The effect of the PAR-2 
agonist was seen similarly on the protein level of IL-8. PAR-2 AP stimulation resulted in 
significant increase of IL-8 concentration in the culture medium (2.0-fold) (Fig. 3.13B). 
In A549 cells the amount of cytokine released was higher than in HSAEC.
In the present work, we found that in A549 cells as well as in primary HSAEC activation 
of PAR-2, but not PAR-1, resulted in the production of the proinflammatory chemokine 
IL-8. 
Further, we investigated the effect of simultaneous treatment with LPS and PAR 
agonists on the IL-8 production by HSAEC. LPS alone induced significant up-regulation 
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of the chemokine expression in HSAEC (2.3 fold). Challenging the HSAEC for 4 h with 
PAR-2  AP  or  thrombin  in  the  presence  of  LPS  amplified  the  IL-8  expression  (Fig. 
3.13A). Like in A549 cells, the IL-8 expression in HSAEC reached the highest level after 
combined stimulation with PAR-2 AP and LPS, compared to the co-stimulation with LPS 
and thrombin or with each stimulus alone. Co-stimulation with LPS and TRag did not 
alter IL-8 expression level compared to the effect of LPS alone in these cells. 
As expected from the effects on the IL-8 mRNA level, the release of IL-8 into the 
culture medium after 24 h of incubation of HSAEC with the PAR agonists in the presence 
of LPS was potentiated (Fig. 3.13B). Again, the co-stimulation with LPS and thrombin or 
PAR-2  AP  resulted  in  greater  IL-8  protein  production  from  A549  cells  than  from 
HSAEC. That is similar to the effects of these stimuli on the IL-8 mRNA level. 
To summarize this part, TRag did not influence the effect of LPS on IL-8 release 
in both A549 and HSAE cells. Similar to the effects observed on transcript levels, the 
highest protein release was achieved when PAR-2 was activated with PAR-2 AP together 
with  concomitant  stimulation  with  LPS.  That  emphasizes  again  the  importance  of 
epithelial PAR-2 receptor in airway pathophysiology.
Table 3.1 summarizes the potentiating effects on IL-8 release of the combined 
stimulation of A549 cells and HSAEC with LPS and PAR-2 AP or thrombin. The effect 
of simultaneous treatment of A549 cells with LPS and thrombin was 4.9 times higher than 
that induced by thrombin alone and 3.2 times higher than that achieved by LPS alone. In 
HSAEC the IL-8 concentration in the cell culture medium was potentiated 1.7 times after 
stimulation with thrombin together with LPS, compared to the effects of each stimulus 
alone. After the combined stimulation of A549 cells with PAR-2 AP and LPS, the IL-8 
protein level was 1.6-times higher than after stimulation by PAR-2 AP alone and 5.5-
times higher  than after  stimulation by LPS alone.  In HSAEC IL-8 concentration was 
potentiated  2.3  and  1.9  times  compared  to  that  induced  by  PAR-2  AP  or  LPS, 
respectively.
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PAR agonist
Potentiation of PAR agonist-
induced
effect by LPS (n-fold)
Potentiation of LPS-induced 
effect by PAR-agonist
(n-fold)
A549 cells HSAEC A549 cells HSAEC
Thrombin 4.9 1.7 3.2 1.7
PAR-2 AP 1.6 2.3 5.5 1.9
Table 3.1: Potentiating effect on IL-8 protein release, induced by simultaneous incubation of 
A549 cells and HSAEC with PAR agonists and LPS. The potentiation effect is shown as n-fold 
increased IL-8 concentration in the cell culture medium after 24 h simultaneous application of the 
PAR agonists (thrombin or PAR-2 AP) together with LPS, relatively to IL-8 concentration after 
stimulation with the PAR agonists alone, and LPS alone, respectively. 
3.3.5 The influence of PAR activation and concomitant stimulation with LPS on 
TGF-β1 expression in A549 cells.
We  also  investigated  the  TGF-β1  mRNA  levels  after  PAR  activation  and 
simultaneous exposure of the cells to LPS. TGF-β1 expression was up-regulated upon 
PAR activation  using  all  PAR agonists.  The  PAR-2 activating  peptide  was  the  most 
potent agent. It induced a 2-fold increase in TGF-β1 transcript.
After simultaneous stimulation with LPS and PAR-2 AP, the TGF-β1 mRNA level 
was up-regulated only after 4 h by 1.6-fold (P<0.01), and was slightly increased after 
application of TRag and LPS. Compared to untreated cells, the TGF-β1 mRNA level was 
not altered after 4 h of stimulation with thrombin together with LPS. After 24 h of co-
incubation with the PAR agonists and LPS, the TGF-β1 mRNA level was comparable to 
the control level or even slightly lower than the control level (Fig. 3.14).
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Figure 3.14: The influence of PAR agonists alone and in combination with LPS on TGF-β1 
expression in A549 cells. Changes in TGF-β1 mRNA level after 4 and 24 hours of incubation 
were estimated by real-time PCR. Modulation of mRNA expression was calculated using GAPDH 
as a reference gene. Data are means ± SE of three independent experiments. Dotted line at “1” 
indicates control level. Grey bars below the graphs indicate the agonist used. ***p<0.001, **p<0.01, 
*p<0.05 as compared with the untreated cells.
The detection of the TGF-β1 release by A549 cells (measured by ELISA after 4 h 
and 24 h of incubation) confirmed that PAR activation leads to a slight increase of TGF-
β1 secretion (60-100% above control) (data not shown).
3.4Role of MAPKs in PAR-mediated IL-8 release from A549 cells.
3.4.1 Influence  of thrombin,  PAR-2 AP and LPS on MAPK phosphorylation in 
A549 cells.
MAPK play an important  role  in various cells  participating in different  immune 
responses. The responses reach from the initiation of the immune response to inducing 
cell  death  .  However,  only little is known about the involvement of MAPKs in PAR-
mediated IL-8 synthesis in airway cells. This following study by Western blot analysis 
addresses the question of whether PAR agonists and LPS (alone and in combination) lead 
to activation of MAPKs in  A549 cells. Figure 3.15 demonstrates that incubation of the 
A549 cells with thrombin (5 U/ml) and PAR-2 AP (200 µM) induced phosphorylation of 
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JNK and ERK1/2. Stimulation with LPS did not influence the levels of ERK1/2 and JNK 
phosphorylation up to 60 min, despite its ability to induce IL-8 production.
Figure 3.15: Activation of ERK1/2 and JNK by PAR agonists. Serum-starved A549 cells were 
exposed to thrombin (5 U/ml) or PAR-2 AP (200 µM) alone or together with LPS (10 µg/ml) for 
5, 15, 30 and 60 min. Representative blots from one experiment are shown (A and B). The cells 
were  incubated  for  5  min  with  medium  alone  (Control)  or  with  thrombin  and  LPS  (LPS
+Thrombin), PAR-2 AP and LPS (LPS+PAR-2 AP), thrombin (Thrombin), PAR-2 AP (PAR-2 
AP),  or LPS (LPS).  Phosphorylation of ERK1/2 and JNK were analyzed by Western blotting 
using the anti-phospho-ERK1/2 and anti-phospho-JNK antibodies (upper panels). Equal amounts 
of protein loading were confirmed using the specific antibodies for total ERK1/2 and JNK (lower 
panels).  The  bands  were  quantified  by  densitometry  and  normalized  by  referring  to  the 
corresponding total amounts (C, D). JNK phosphorylation was quantified by taking the 46 kDA 
isoform band densitometry and normalized by referring to the corresponding total amount of 46 
kDA JNK isoform. Data are shown as -fold induction compared to control (untreated cells) and 
represent the means ± SE of at least three independent experiments; ap<0.001, bp<0.01, cp<0.05 as 
compared with the untreated cells. Horizontal lines indicate time periods of cell stimulation. 
Phosphorylation of ERK1/2 after  stimulation with either thrombin or PAR-2 AP 
was maximal at 5 min (400% of control) and then gradually declined, almost reaching the 
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basal level by 60 min of incubation (Fig. 3.15C). When A549 cells were stimulated with 
thrombin or PAR-2 AP together with LPS, the degree of phosphorylation was comparable 
to that obtained with thrombin or PAR-2 agonist alone. Stimulation with PAR-2 AP alone 
or together with LPS induced ERK1/2 phosphorylation which was slightly stronger than 
that caused by thrombin or thrombin with LPS.
JNK phosphorylation was smaller than that of ERK1/2 (200%) and persisted for at 
least 1 h (Fig. 3.15D). The effect of thrombin (alone and in combination with LPS) was 
retained up to 60 min, whereas stimulation with PAR-2 AP (alone or with LPS) induced 
maximal phosphorylation level at 30 min.
3.4.2 Inhibition of ERK1/2 or of JNK decreases the production of IL-8 in response 
to thrombin and PAR-2 AP, either alone or together with LPS.
Using specific pharmacological inhibitors of the MAPK cascade, the involvement of 
the MAPK family in PAR-mediated IL-8 release in A549 cells  was investigated (Fig. 
3.16). A blockade of p38 MAPK by SB203580 (10 µM) failed to affect the secretion of 
IL-8, which was induced by stimulation with thrombin, and PAR-2 AP, either alone or in 
combination with LPS.
Figure 3.16: Effect of MAPK inhibitors on PAR induced IL-8 release in A549 cells. 
Serum-starved cells were pretreated with either p38 MAPK inhibitor SB203580 (10 µM), 
JNK inhibitor SP600125 (10 µM) or ERK1/2 inhibitor U0126 (20 µM) for 30 min, followed 
by  incubation  with  medium or  thrombin  (5  U/ml),  PAR-2  AP  (200  µM),  alone  or  in 
combination with LPS (10 µg/ml) for the next 24 h. An ELISA was used to quantify the 
amount of released IL-8. The results are means ± SE of three independent experiments. ; 
***p<0.001, **p<0.01, *p<0.05 as compared with the cells exposed to only agonists (without 
inhibitor).
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Pretreatment of the cells with the JNK inhibitor SP600125 (10 µM) reduced the 
IL-8 release after incubation with thrombin or PAR-2 AP by 30 and 40%, respectively. 
SP600125 abolished by 50% the cytokine release induced by the combined stimulation of 
the cells with PAR agonists together with LPS. A MEK1/2 inhibitor, U0126 (20 µM), 
showed  an  80%  reduction  of  the  IL-8  production,  which  was  caused  by  combined 
incubation with thrombin or PAR-2 AP together with LPS. The thrombin- or PAR-2 AP-
induced IL-8 secretion was inhibited by U0126 by 60%. These results are consistent with 
the ERK and JNK phosphorylation data shown above in Figure 3.15.
3.5 PAR-3 signaling
From  the  experiments  presented  above  PAR-3  attracted  our  special  attention. 
Firstly, the PAR-3 mRNA level was down-regulated after prolonged incubation of A549 
cells with PAR agonists together with LPS. Secondly, stimulation of the A549 cells with 
thrombin  but  not  with  PAR-1-activating  peptide  increased  production  of  the  pro-
inflammatory cytokine IL-8. These interesting observations led us to assume that PAR-3, 
the most elusive receptor within the PAR family, plays a role in inflammatory reactions 
and is directly involved in IL-8 production.
In  order  to  assess  our  hypothesis  about  an  important  function  of  PAR-3,  we 
engineered  exogenous  human  PAR-3  expression.  The  full-length  human  PAR-3  was 
cloned  by  PCR amplification  into  the  pEGFP-N1  vector  (see  Materials  & Methods). 
Further, this GFP-tagged PAR-3 was stably transfected using Lipotransfection into human 
embryonic kidney cells (HEK-293). The obtained HEK-PAR3-GFP cell line was used in 
further experiments. As a reference served HEK-293 cells transfected with pEGFP-N1 
plasmid DNA (HEK-GFP) and HEK-293 wildtype cells (HEK-WT). 
Quantification  of  relative  expression  of  PAR-3  in  HEK-PAR3-GFP  showed 
significant expression of PAR-3. It was about 100-fold compared with the endogenous 
PAR-1 expression level.  PAR-3 was not expressed  by HEK-WT and HEK-GFP cells 
(Fig. 3.17A). Transfection of the cells had no influence on the PAR-1 mRNA level. The 
PAR-3-GFP fusion protein was found to be localized on the plasma membrane due to the 
green fluorescence of GFP, and there was very little cytoplasmic distribution (Fig.3.17B). 
GFP  in  HEK-GFP  cells  was  visible  in  the  whole  cell  without  staining  of  particular 
organelles.
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Figure 3.17: Detection and localization of PAR-3 in PAR-3-transfected HEK-293 cells. A: 
RT-PCR analysis of PAR-1 and PAR-3 in PAR-3-GFP- or GFP-transfected HEK and wild-type 
HEK cells: Total RNA was isolated and used for real-time PCR. Modulation of mRNA expression 
was calculated using GAPDH as a reference gene. Data are means ± SE of three independent 
experiments.  Dotted  line  at  “1”  indicates  control  level.  PAR expression  levels  are  expressed 
relative to the PAR-1 mRNA expression in HEK-WT cells, which was arbitrarily chosen as a 
reference value of 1. N.D. stands for not detected. B: PAR-3-GFP and GFP were detected by GFP 
fluorescence using LSM510 confocal laser scanning microscope (Carl Zeiss, Germany). Images 
are representative for three different experiments.
To confirm the functional expression of PAR-3, we used thrombin, which is the 
only PAR-3 agonist known till  now. We tested the induction of an increase in [Ca2+]i. 
Since HEK-293 cells endogenously express another thrombin receptor, namely PAR-1, 
HEK-GFP cells were used in parallel for proper evaluation of our experimental concept.
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The  concentration-response  curves  were  obtained  by  analyzing  the  thrombin-
induced  Ca2+ mobilization  for  both  cell  lines  as  represented  in  Figure  3.18.  The 
application  of  thrombin  to  HEK-PAR3-GFP  cells  resulted  in  significantly  higher 
(appprox. 3 times) amplitude of Ca2+ responses than in HEK-GFP cells.  The maximal 
response was achieved at a concentration of 10 U/ml thrombin for both cell types. This 
clearly indicates that PAR-3 used in our studies is functionally expressed and mediates 
cellular Ca2+ signaling, upon stimulation with thrombin.
Figure  3.18: Concentration–response  curves  for  thrombin  in  inducing  [Ca2+]i rise  in 
HEK-293 cells  stably  expressing  the PAR-3 receptor GFP fusion protein  and only  GFP 
protein.  The fura-2-AM-loaded cells were stimulated with varying concentrations of thrombin, 
and the change in fluorescence (ΔF340 nm  /F380 nm) was detected. Data represent the mean ±  s.e.m. 
from 70 to 150 single cells, which were measured in at least three separate experiments (in some 
cases the error bars are smaller in size than the symbols used).
Next,  we  wanted  to  clarify  whether  the  expression  of  PAR-3  is  modulated  by 
thrombin.  Since  both  PAR-1  and  PAR-3  are  thrombin  receptors,  it  is  of  interest  to 
elucidate the possible differences in thrombin-mediated changes of the transcript levels of 
these two receptors.  With the help of real-time PCR we assessed the alteration of the 
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expression of the endogenous PAR-1 and the overexpressed PAR-3, after exposure of the 
cells to thrombin (10 U/ml).
Activation of the HEK-PAR3-GFP cells with thrombin for 3 h or 6 h had no effect 
on the PAR-1 mRNA level. However, the PAR-3 mRNA expression was significantly up-
regulated (Fig. 3.19). Similarly,  in control cells,  HEK-GFP and HEK-WT, the PAR-1 
mRNA level was also not influenced by the exposure of the cells to thrombin.
Figure 3.19: Effect of thrombin on the expression level of PAR-1 in HEK-PAR3-GFP, 
HEK-GFP and HEK-WT cells and PAR-3 level in HEK-PAR3-GFP cells. Changes in 
PAR-1 (black bars) and PAR-3 (grey bars) mRNA level after incubation with 10 U/ml 
thrombin for 3 h or 6 h. Total RNA was isolated and used for real-time PCR. Modulation of 
mRNA expression was calculated using GAPDH as a reference gene. Data are means ± SE 
of three independent experiments. Dotted line at “1” indicates control level. ***p<0.001, 
**p<0.01 as compared with the respective untreated cells.
To address  the  question  of  whether  PAR-3 activation  can  lead  to  other  cellular 
responses,  we studied the effect  of  thrombin on IL-8 production in  HEK cells  stably 
expressing PAR-3. IL-8 synthesis was greatly enhanced in HEK-293 cells overexpressing 
PAR-3 upon stimulation with thrombin both on mRNA and protein level. The increase 
was up to 30- and 25-fold, respectively (Fig. 3.20). The IL-8 production by HEK-WT and 
HEK-GFP  was  not  influenced  by  exposure  to  thrombin  demonstrating  that  PAR-3-
deficient cells do not respond to thrombin to release IL-8.
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Figure 3.20: Effect of thrombin on the expression of IL-8 mRNA level and on protein 
secretion in HEK-PAR3-GFP cells. The HEK-PAR3-GFP, HEK-GFP and HEK-WT cells 
were incubated with 10 U/ml thrombin. A: Changes in IL-8 mRNA level after 3 and 6 hours 
of  stimulation  were  estimated  by real-time  PCR. Modulation  of mRNA expression  was 
calculated using GAPDH as a reference gene. B: Secreted IL-8 in the medium after 6 hours 
of incubation quantified by ELISA. Data are means ± SE of three independent experiments. 
Dotted  line  at  “1”  indicates  control  level.  ***p<0.001,  **p<0.01  as  compared  with  the 
respective untreated cells.
To  exclude  the  possibility  that  the  thrombin-mediated  IL-8  release  is  due  to 
activation of PAR-1 or that PAR-3 participates in a dual receptor system as a thrombin 
cofactor  for  PAR-1  activation,  we  performed  gene  silencing  of  PAR-1,  using  target 
sequence-specific  small  interfering  RNA  (siRNA).  HEK-PAR3-GFP  cells  were  co-
transfected  with  100 nM of  PAR-1 siRNA or  with  AllStars  negative  control  siRNA. 
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Transfection with PAR-1 siRNA for  48  h resulted  in  highly suppressed  (about  80%) 
PAR-1  transcript  level.  The  control  siRNA  did  not  interfere  with  PAR-1  mRNA 
expression (Fig. 3.21A).
Additionally, the [Ca2+]i rise after PAR-1 activation was verified. Specific activation 
of PAR-1 with TRag induced a significantly lower [Ca2+]i response in cells transfected 
with PAR-1 siRNA than in untransfected cells or in cells transfected with control siRNA 
(Fig. 3.21B). Therefore, we can conclude that PAR-1 siRNA significantly decreases both 
PAR-1 expression and the function in terms of Ca2+ signaling.
Figure 3.21: Suppression of PAR-1 expression by siRNA. HEK-PAR3-GFP cells were 
transiently  transfected  with  either  PAR-1  siRNA  or  control  siRNA.  Quantification  of 
PAR-1 expression was assessed by real-time PCR (A). Measurements were normalized to 
the  GAPDH  mRNA  level.  The  values  given  are  means  ±  SE  of  three  independent 
measurements.  PAR-1  expression  level  is  expressed  relative  to  the  PAR-1  mRNA 
expression  in  cells  transfected  with  control  siRNA,  which  was  arbitrarily  chosen  as  a 
reference value of 1. [Ca2+]i rise in HEK-PAR3-GFP induced by PAR-1 activating peptide 
(TRag)  (B). The fura-2-AM loaded HEK-PAR3-GFP cells and HEK-PAR3GFP cells co-
transfected with PAR1 siRNA or control siRNA were exposed to TRag (10 µM) and the 
changes  in  fluorescence  (ΔF340  nm  /F380 nm)  were  detected.  The  traces  are  the  mean  of 
minimally 25 single cells measured in one experiment and are representative for at least 
three different experiments
Furthermore, siRNA-transfected HEK-PAR3-GFP cells were incubated for 6 h with 
10 µM TRag or 10 U/ml thrombin. The PAR-1 mRNA level in cells treated with control 
siRNA decreased slightly after stimulation with TRag and thrombin. However, the PAR-3 
mRNA level was up-regulated significantly, about 3-fold, upon treatment with thrombin 
in both cells, transfected with PAR-1 siRNA and control siRNA. This is comparable to 
the results presented above with HEK-PAR3-GFP (Fig. 3.19).
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Figure 3.22: Effect  of  TRag and thrombin  on the expression levels  of  PAR-1 and 
PAR-3  in  HEK-PAR3-GFP  cells  transfected  either  with  PAR-1  siRNA  or  control 
siRNA. Changes  in  PAR-1  mRNA  level  (A) and  in  PAR-3  mRNA  level  (B) after 
incubation with 10 µM TRag or 10 U/ml Thrombin for 6 h were estimated by real-time 
PCR. Modulation of mRNA expression was calculated using GAPDH as a reference gene. 
Data are means ± SE of three independent experiments. Dotted line at “1” indicates control 
level. ***p<0.001, *p<0.05 as compared with the untreated cells. 
These results provide convincing evidence that thrombin-induced up-regulation of 
PAR-3 expression is independent from PAR-1 activation.
Similarly,  as shown in Fig.  3.23A, treatment  with thrombin,  but not with TRag, 
significantly elevated the synthesis of IL-8 mRNA by 20- and 22-fold (P<0.05) in HEK-
PAR3-GFP cells  transfected with PAR-1 siRNA and in cells  transfected  with control 
siRNA, respectively. Consequently, thrombin induced a significant increase of IL-8 in the 
cell culture supernatant of these cells (13- and 17-fold, respectively) (Fig. 3.23B). This 
highly enhanced amount of IL-8 released from the HEK cells expressing PAR-3 upon 
exposure to thrombin did not differ significantly between cells transfected with PAR-1 
siRNA and control siRNA
Therefore, it can be concluded that suppression of endogenous PAR-1 expression in 
HEK-PAR3-GFP cells had no significant influence on the synthesis and protein secretion 
of IL-8 induced by thrombin. This indicates that PAR-3-mediated IL-8 production is not 
dependent on PAR-1 co-expression.
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Figure 3.23: Effect of TRag and thrombin on the expression of IL-8 mRNA level and 
protein secretion in HEK-PAR3-GFP cells transfected with PAR1 siRNA. Changes in 
IL-8 mRNA level by real-time PCR (A) protein secretion by ELISA (B) after incubation of 
HEK-PAR3-GFP cells transfected either with PAR1 siRNA or control siRNA with 10 µM 
TRag or10 U/ml thrombin for 6 h. Total RNA was isolated and used for real-time PCR. 
Modulation of mRNA expression was calculated using GAPDH as a reference gene. Data 
are means ± SE of three independent experiments. Dotted line at „1“ indicates control level. 
***p<0.001, *p<0.05 as compared with the respective untreated cells. 
It  has  been  shown that  PAR-1 and PAR-2 can  affect  cellular  functions  through 
different  signal  transduction  pathways,  including  the  MAPK  pathway.  Furthermore, 
MAPK cascades are involved in PAR-1 and PAR-2-induced IL-8 production . However, 
until  now,  there  is  no  data  available  showing the  participation  of  MAPKs in  PAR-3 
signaling. In this work, the involvement of MAPKs, ERK1/2, JNK and p38 MAPK, in 
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PAR-3-mediated  production  of  IL-8  was  investigated  using  specific  inhibitors.  The 
HEK-293 cells overexpressing PAR-3 were pre-incubated with 10 µM of the p38 MAPK 
inhibitor SB203580, 10 µM of the JNK inhibitor SP600125 and 20 µM of the ERK1/2 
inhibitor U0126, followed by the stimulation with 10 U/ml thrombin. As shown in Figure 
3.24, a blockade of JNK and ERK1/2 reduced the IL-8 secretion induced by thrombin by 
about  40% and  by  77%,  respectively.  Pretreatment  of  the  cells  with  the  p38  MAPK 
inhibitor did not significantly affect the IL-8 production.
Figure 3.24: Effect of MAPK inhibitors on thrombin-induced IL-8 release in HEK-
PAR3-GFP cells. Serum-starved cells were pretreated with either the p38 MAPK inhibitor 
SB203580 (10 µM), the JNK inhibitor SP600125 (10 µM) or the ERK1/2 inhibitor U0126 
(20 µM) for 30 min, followed by incubation with 10 U/ml thrombin for 6 h. An ELISA was 
used  to  quantify  the  amount  of  IL-8  released.  The  results  are  means  ±  SE  of  three 
independent  experiments.  ***p<0.001,  *p<0.05  as  compared  with  the  cells  treated  with 
thrombin only.
By Western blot analysis we confirmed that thrombin activates ERK1/2 in HEK-
PAR3-GFP cells. Figure 3.25 demonstrates that incubation of these cells with thrombin 
(10  U/ml)  highly  induced  the  time-dependent  phosphorylation  of  ERK1/2  (up  to  26-
times)  in  HEK-PAR3-GFP  cells,  expressing  endogenous  PAR-1.  Also  in  the  cells 
transfected with PAR-1 siRNA there was an increase of up to 21-times above the control 
level. Only, after 5 min of incubation with thrombin, there seemed to be a difference in 
phosphorylation levels between HEK-PAR3-GFP cells and the cells with silenced PAR-1. 
The ERK1/2 activation was 50% higher in HEK-PAR3-GFP cells expressing endogenous 
PAR-1 than in cells co-transfected with PAR-1 siRNA. After 10 min of incubation the 
ERK1/2 phosphorylation in these two cell lines reached a similar level. These results are 
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presented  in  Figure  3.25A  as  time-course  showing  representative  blots,  which  are 
quantified in Figure 3.25B.
Figure  3.25:  Activation of  ERK1/2  by  thrombin  in  HEK-PAR3-GFP,  HEK-PAR3-
GFP  deficient  in  PAR-1  and  HEK-GFP  cells. Serum-starved  cells  were  exposed  to 
thrombin (10 U/ml) for 5, 10 and 30 min. Phosphorylation of ERK1/2 was analyzed by 
Western  blotting  using  the  anti-phospho-ERK1/2  antibodies.  Equal  amounts  of  protein 
loading  were  confirmed with  the  antibodies  specific  for  total  ERK1/2.  The bands were 
quantified by densitometry and normalized by referring to the corresponding total amount 
of ERK1/2. Cells without treatment with thrombin served as control (100%), indicated by 
dotted line at “1”. The results are means ± SE of three independent experiments. + p<0.001 
as compared to the cells without treatment with thrombin.
JNK phosphorylation was considerably smaller than that of ERK1/2 and reached a 
maximal  level  of  200%  of  control  value  in  HEK-PAR3-GFP  cells  after  thrombin 
treatment (Fig.3.26).
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Figure 3.26: Activation of JNK by thrombin in HEK-PAR3-GFP, HEK-PAR3-GFP 
deficient in PAR-1 and HEK-GFP cells. Serum-starved cells  were exposed to thrombin (10 
U/ml) for 5, 10 and 30 min. Phosphorylation of JNK was analyzed by Western blotting using the 
anti-phospho-JNK  antibodies.  Equal  amounts  of  protein  loading  were  confirmed  with  the 
antibodies specific for total JNK. The bands were quantified by densitometry and normalized by 
referring to the corresponding total amount of JNK. Cells without treatment with thrombin served 
as  control  (100%),  indicated  by  dotted  line  at  “1”.  The  results  are  means  ±  SE  of  three 
independent experiments. + p < 0.001, # p < 0.005 as compared to the cells without treatment with 
thrombin.
In  the  HEK-PAR3-GFP  cells  transfected  with  PAR-1  siRNA,  this  effect  was 
reduced by about 40-80%.
p38 MAPK was not activated by exposure to thrombin in HEK-293 cells expressing 
PAR-3 (data not shown).
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4 Discussion
4.1 Functional expression of PARs in airway epithelial cells.
The results presented here demonstrate that A549, HBE and primary HSAE cells, 
lung  epithelial  cells,  express  two  PAR  subtypes,  PAR-1  and  PAR-2.  A549  cells 
additionally express PAR-3 that was confirmed by RT-PCR and immunocytochemistry. 
Functional  expression  of  these  PARs  in  all  lung  epithelial  cells  investigated  was 
confirmed by monitoring the changes  of  [Ca2+]i induced by  PAR-1 and -2 activating 
peptides as well as by stimulation with thrombin and trypsin. All methods used, RT-PCR, 
immunocytochemistry  and  measurement  of  [Ca2+]i indicate  predominance  of  PAR-2 
mRNA and protein expression and function. The  detection of PAR-4 by RT-PCR and 
Ca2+ mobilization studies gave negative results,  so we can accept that PAR-4 was not 
expressed by any of the cells. In conclusion, PAR-2 is the main functionally expressed 
PAR receptor on lung epithelial cells.
4.2 Evaluation of PAR activation by trypsin isoforms in airway epithelial cells.
The further aim of this study was to extend the knowledge about trypsin-mediated 
PAR activation on human lung epithelial cells by investigating the ability of different 
human trypsin isoforms to activate PARs.
The measurements of [Ca2+]i were performed in the human epithelial A549 and 
HBE cell lines. The results clearly demonstrate that mesotrypsin failed to produce Ca2+ 
responses in epithelial  cells  even at high concentrations, whereas cationic and anionic 
trypsins showed typical activity, comparable to that of bovine trypsin in epithelial cells. 
The ability of the cationic and anionic trypsin isoforms to activate Ca2+ signaling 
in  lung epithelial  cells  directly  through the interaction with PAR-2 was confirmed in 
desensitization assays in HBE cells. However, mesotrypsin does not seem to be a potent 
activator of PAR-2. This finding is somehow in contradiction to studies of the Bunnet 
group . They have found that trypsin IV can evoke a Ca2+ response via PAR-2 and PAR-4 
in cells overexpressing these receptors. Similarly, epithelial cells, like A549 cells, besides 
endogenous PAR-2 also express enteropeptidase that cleaves trypsinogen IV released by 
the cells. That consequently causes PAR-2 and PAR-4 activation. The reason for these 
discrepancies  can  be  the  fact  that  this  group  applied  in  their  investigations 
enteropeptidase-activated conditioned medium from CHO-Igκ-TIV cells that may contain 
other substances that display proteolytic activity. We used purified, active recombinant 
trypsin.  Furthermore,  the recent report  from the same research group demonstrates on 
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transfected cells that human trypsin IV activates PAR-1 and PAR-2 with similar potencies 
. It seems that the capacity of mesotrypsin/trypsin IV to activate PARs may depend on the 
preparation of the enzyme, and cell type- and species-specific PAR expression. It has to 
be also mentioned that trypsinogen IV is an alternatively spliced form of mesotrypsinogen 
and the amino acid sequences of the N-terminus encoded by the alternative exon 1 are 
completely different. Therefore trypsin IV lacks a recognizable signal sequence .
Originally, trypsinogen IV was found to be expressed in the human brain . It was 
shown that trypsinogen IV expression leads in mouse neurons to a massive increase of 
glial  fibrillar  acidic protein expression in astrocytes  as  well  as to the lack of amyloid 
deposits  in  trypsinogen  IV  transgenic  mice  .  Mesotrypsin/trypsin  IV  causes  PAR-
dependent oedema with granulocyte infiltration and induces hyperalgesia to thermal and 
mechanical stimuli in mice paw . Thus, mesotrypsin/trypsin IV contributes to neurogenic 
inflammation  and  pain.  These  results  together  with  mesotrypsin's  resistance  to 
polypeptide  trypsin  inhibitors,  which  are  present  in  the  brain  ,  suggest  a  special 
physiological  role  of  this  trypsin  isoform  in  the  human  brain.  However,  it  is  still 
controversial, which PAR is activated by mesotrypsin/trypsin IV. To explore the ability of 
mesotrypsin  to  activate  PARs  in  brain  tissue, human  astrocytoma  1321N1  cells 
expressing  functional  PAR-1,  PAR-3  and  no  PAR-2  were  used.  The  functionality  of 
PAR-1 was confirmed by measurement of TRag-induced [Ca2+]i rise, whereas PAR-2 AP 
was completely ineffective.  Astrocytoma cells  demonstrated lower susceptibility to be 
activated by bovine trypsin as compared to the epithelial cells. The lower potency of both 
cationic and anionic trypsin isoforms as compared to that in HBE cells was evident from 
the analysis of the concentration response curves. The EC50 value of these isoforms in 
1321N1 cells  was  determined  to  be  20  nM and  10  nM,  respectively.  Similar  to  the 
epithelial cells, cationic trypsin-produced effects in 1321N1 cells were more pronounced 
than  those  by  anionic  trypsin.  Interestingly,  in  contrast  to  the  epithelial  cell  lines, 
mesotrypsin was definitely effective in 1321N1 cells, although with an EC50 value of 60 
nM, which is 3-5-fold higher than that of cationic and anionic trypsin.
Taking into account the ability of trypsin to activate both PAR-1 and PAR-2 and the 
absence of PAR-2 in 1321N1 cells, we can suggest that trypsin initiates the signaling in 
the  human  astrocytoma  cells  through  PAR-1.  This  was  confirmed  by  the  results  of 
desensitization  assays  in  1321N1  cells  in  which  responses  to  trypsin  isoforms  were 
significantly diminished after PAR-1 desensitization with TRag. Stimulation of PAR-1 in 
1321N1  cells  by  10  µM  of  the  receptor-specific  agonist  peptide  TRag  before  the 
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applications  of  cationic  and  anionic  trypsin  as  well  as  mesotrypsin  resulted  in 
approximately 50% decrease of Ca2+ responses produced by these trypsin isoforms. These 
are clear evidences demonstrating that all three trypsin isoforms mediate their effects in 
the cells through PAR-1 as well.
Like in epithelial cells, anionic and cationic trypsin isoforms displayed an activity 
in 1321N1 cells similar to that of commercial trypsin. In contrast to epithelial cells, high 
concentrations of mesotrypsin produced significant Ca2+ responses in astrocytoma cells, 
suggesting that mesotrypsin can be considered as a potent activator of PAR-1 in brain 
cells.  Supporting  evidence  was  shown  by  another  study  from  our  laboratory  .  Data 
obtained  during  these  investigations  revealed  that,  similarly  to  the  human  system, 
mesotrypsin  activates  PAR-1  also  in  rat  astrocytes,  however  with  much  higher 
effectiveness. This indicates a physiological role of mesotrypsin with regard to the Ca2+ 
response in brain cells.
Such differences between cells from different tissue origin can be due to specific 
properties of the receptor in the particular tissue. At present several possibilities can be 
suggested concerning the state of PARs:  either tissue- and species-specific mutations or 
glycosylation pattern, which were both shown to be able to influence receptor activation .
In summary, it can be concluded that PAR-2 is a substrate for both cationic and 
anionic trypsin isoforms in human epithelial  cells.  Different from these two isoforms, 
mesotrypsin demonstrates distinct properties and activates neither PAR-1 nor PAR-2 in 
human epithelial cells. Interestingly, according to our results on human astrocytoma cells 
and the data on rat astrocytes, this trypsin isoform may be a potential activator of PAR-1 
in the brain participating in protection / degeneration processes in brain tissue. However, 
in the lung epithelial cell, in contrast to cationic and anionic trypsin, mesotrypsin does not 
seem to play a physiological role.
4.3Inflammatory mediators LPS, TNF-α, IL-8 and PGE2 regulate PAR expression 
in A549 cells.
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Pulmonary  epithelial  cells  are  the  first  line  of  host  defence  against  inhaled 
pathogens. However, there is increasing evidence that the airway epithelium is not only a 
passive barrier against microbial components but is also an active player in the innate 
immune response of the lung and in the development of chronic inflammation.
The  respiratory  epithelium  can  generate  various  immune  mediators,  such  as 
cytokines,  chemokines,  and  anti-microbial  peptides  (e.g.  defensins)  and  regulate  the 
activation  and  recruitment  of  phagocytes  and  lymphocytes.  Particularly  chronic 
inflammatory  diseases,  such  as  asthma,  are  associated  with  epithelial  damage  and 
alteration  of  the  epithelial  phenotype.  The  cells  persistently  express  abnormally  high 
levels  of bioactive  molecules  and surface receptors  and thus are  able  to  maintain the 
ongoing inflammation.  PARs are  involved in the regulation of epithelial  responses  to 
injury.
However,  there  is  still  limited  information  concerning  the  question  which 
particular  factors  can  modulate  PAR  expression  on  airway  cells.  Therefore,  the 
investigation of the effect of inflammatory mediators and persistent PAR activation by 
their  agonists  provide  important  evidence  for  the  involvement  of  PARs  in  many 
pathological conditions.
Bacteria  colonize  the  airways  inducing  inflammation  and  release  of  numerous 
potent  inflammatory  molecules,  including  endotoxin,  peptidoglycan  fragments,  outer 
membrane lipoproteins, lipoteichoic acid, microbial toxins . LPS, a cell wall component 
of gram-negative bacteria, is a common occupational air contaminant, which causes both 
acute  and  chronic  airflow  obstruction,  airway  inflammation  and  airway  remodeling. 
Respiratory  epithelial  cells  along  with  alveolar  macrophages  are  a  target  for  this 
endotoxin. Inhaled LPS forms complexes with LPS-binding protein, interacts with CD14 
that initiates cell signaling via Toll-like receptor 4 associated with the accessory molecule 
MD-2.  This  leads  to  signaling cascades  that  finally  result  in  the biosynthesis  of  pro-
inflammatory  cytokines  .  Another  inflammatory  mediator,  TNF-α,  an  early 
proinflammatory  cytokine,  which  can  be  released  by  blood  monocytes  and  alveolar 
macrophages after LPS stimulation, has many proinflammatory effects in common with 
LPS, resulting in the pathogenesis of lung injury.
Epithelial  cells,  upon  activation  by  either  LPS  or  TNF-α  release  different 
chemokines,  cytokines,  defensins  and adhesion  molecules.  Besides  the  release  of  the 
inflammatory agents from the cells, LPS and TNF-α can modulate cellular responsiveness 
to subsequent stimuli via alteration of expression of cell-surface receptors . 
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In the present study, we showed that although both agents, LPS and TNF-α, can up-
regulate  PAR  expression  in  A549  cells,  they  display  different  time  dependence  and 
selectivity towards particular PAR subtypes. LPS affected exclusively PAR-2 that was 
observed  only  after  short-term  stimulation.  A  similar  selectivity  of  LPS towards  up-
regulation of PAR-2 was seen for endothelial cells . The effect of TNF-α occurred after 
prolonged incubation and influenced the expression of all three PARs in A549 cells.
Interestingly,  another  proinflammatory  cytokine,  IL-8,  which  is  also  rapidly 
produced by immune cells and by epithelial cells themselves after LPS challenge, had an 
effect  opposite  to  that  of  TNF-α.  After  long-term  stimulation,  IL-8  slightly  down-
regulated the PAR expression, especially PAR-2.
Under normal conditions, the epithelial cells produce proinflammatory chemokines 
and anti-inflammatory molecules, e.g. surfactant proteins, in a highly balanced manner, 
and  the  cell  response  to  the  exposure  of  inhaled  LPS  is  dampened.  Considering  the 
expression  of  CXCR1  and  2,  receptors  for  IL-8,  on  airway  epithelial  cells  ,  the 
IL-8/CXCR1,2  axis  may  contribute  to  dampening  cellular  inflammatory  responses  in 
autocrine  fashion  under  healthy  conditions.  In  support  of  this,  we observed  that  low 
(picomolar) concentrations of IL-8 that reflects the chemokine concentrations determined 
in BALF of healthy subjects  ,  but not higher (nanomolar)  IL-8 concentrations,  down-
regulated the expression of PAR-2 on airway epithelial cells (data not shown).
Therefore, it can be assumed that under physiological conditions the regulation of 
the level of PAR-2 is under the control of a negative feedback mechanism. Only when the 
burst of inflammatory reactions cannot be controlled and suppressed any more, PAR-2 
participates actively in the development of proinflammatory responses. 
Moreover,  PAR-2,  among  all  three  PARs,  was  essentially  influenced  by  PGE2. 
Considering the fact  that  activation of epithelial  PAR-2 induces the release of PGE2 , 
down-regulation  of  PAR-2  by  PGE2 observed  in  our  studies  further  supports  the 
hypothesis about the presence of the PAR-2-PGE2-prostanoid receptor EP axis in airway 
epithelium . Moreover, it has been postulated that the interplay between PAR-2, PGE2 and 
its receptor predominantly produces anti-inflammatory effects within the lung.
Furthermore, a correlation between the modulation of PAR-2 mRNA synthesis and 
changes in IL-8 and TGF-β1 expression upon stimulation with inflammatory agents was 
observed. It means that the up-regulation of PAR-2 transcripts after stimulation with LPS 
or TNF-α was accompanied by increase in IL-8 expression level. Similarly, exposure to 
TNF-α and PGE2 induced increase in PAR-2 and TGF-β1 transcript. On the contrary, the 
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down-regulation of PAR-2 expression induced by 24-h-exposure of the cells to IL-8 was 
observed together with reduced IL-8 mRNA level.  Similarly, PGE2 over 10 h induced 
slight down-regulation of PAR-2 as well as IL-8 expression.
Therefore, it can be speculated that PAR-2 belongs to the inflammatory network in 
lung and actively participates in regulation of ongoing inflammation and attraction of 
neutrophils.
4.4 Continuous PAR activation and simultaneous exposure to endotoxin modulate 
PAR expression in airway epithelial cells.
Both acute lung injury and chronic lung diseases, such as asthma, are accompanied 
by increased  activity  of  the coagulant  proteases,  as  a  result  of  vascular  leakage,  and 
proteases from immune cells.  Among those proteases are thrombin  ,  tryptase ,  human 
airway trypsin-like protease (HAT)  that possess the ability to activate PARs. However, it 
is not clear whether PAR activation can modulate PAR expression and susceptibility on 
airway cells. Therefore, it is important to evaluate the feedback influence of persisting 
PAR activation on PAR expression.
In  the  present  study  we  showed  that  continuous  activation  of  both  PAR-1  and 
PAR-2 caused up-regulation of expression of these receptors in A549 cells, while PAR-3 
expression  was  not  influenced.  This  effect  was  seen  for  up  to  24  h  of  incubation. 
Moreover,  activation  of  PAR-2 resulted  in  higher  up-regulation  of  the  receptors  than 
activation of PAR-1. The high susceptibility of PAR-2 to persistent PAR activation was 
confirmed also with primary HASEC and HBE cells. In HSAEC, activation of PAR-2 
induced increased transcript levels of PAR-2, whereas PAR-1 agonist exhibited no effect 
on PAR expression level. In HBE cells, activation of both receptors PAR-1 and PAR-2 
induced  up-regulation  of  PAR-2  mRNA  level.  Studies  on  the  consequences  of 
simultaneous occurrence of PAR activation and bacterial pathogen invasion represent an 
important issue for the better understanding of lung infectious and inflammatory diseases. 
Therefore we assessed the interaction between PAR agonists and LPS. The combination 
of PAR-1 or PAR-2 agonists with LPS abrogated the effects on PAR-1 expression during 
all periods of incubation. At the same time, the PAR-2 expression level remained up-
regulated after short stimulation only with the combination of LPS and PAR-2 AP. Thus, 
the elevation of expression of PAR-2 occurs to a higher extent than that of the other PARs 
and it persists even under those conditions, which decrease the expression of PAR-1. This 
is in line with the observations made in animal models of lung injury which showed that 
76
Discussion
rat bronchi after LPS treatment exhibited increased levels of PAR-2 on the epithelium 
and, as a consequence, increased responsiveness to PAR-2 activation . Taken together, 
these data  underline  the importance  of epithelial  PAR-2 and PAR-2 activators  during 
acute and chronic inflammation.
Interestingly, prolonged incubation with PAR agonists together with LPS resulted in 
down-regulation  of  the PAR-3 level.  This  implies  that  PAR-3 can play  a  role  in  the 
development of inflammation in the human lung.
The control of PAR-1, -2 and -3 expression exerted by PAR activation by PAR-1 
AP  or  PAR-2  AP  and  exposure  to  LPS,  which  we  observed  in  epithelial  cells  is 
schematically summarized in Figure 4.1.
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Figure 4.1:  Scheme summarizing the effects of the exposure of lung epithelial cells to 
PAR agonists and LPS on PAR expression level. Application of PAR agonists and LPS as a single 
stimulus as well as the combined application are marked on top of the scheme in boxes within 
dotted frames. The effects of the stimulation of the cells with these agonists, given as “Response 
1” (PAR-1  expression),  “Response  2” (PAR-2  expression)  and  “Response  3” (PAR-3 
expression)  are  presented  below.  The  thickness  of  the  arrows  illustrates  the  strength  of  the 
response. The dashed arrows with a cross portray the lack of influence of the respective agonist.
However, it should be noted that pathological situations in vivo are characterized by 
the action of multiple factors. Each of them can potentiate or abolish the effects of others. 
Therefore, the receptor expression level is a result of complex interactions.
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4.5 PAR activation stimulates and potentiates the LPS-induced IL-8 production.
In  the  present  study,  using  primary  airway  epithelial  cells  (HASEC)  and  an 
epithelial  cell  line  (A549),  we  found  that  PAR-2  agonists  and  LPS  substantially 
potentiated each other’s effects on the mRNA synthesis and release of IL-8 from the cells. 
We can conclude that epithelial PAR-2 synergistically with LPS intensifies neutrophil 
recruitment  during  bacterial  infection.  In  agreement  with  this,  PAR-2-deficient  mice 
compared to wild-type animals showed lowered leukocyte rolling and reduced content of 
myeloperoxidase,  a  neutrophil  marker.  This  was  seen after  surgical  trauma and LPS-
induced damage, respectively .
Asthmatic conditions and viral infection sensitize airways to noxious agents and are 
characterized  by  airway  hyper-responsiveness.  Disbalanced  overproduction  of 
proinflammatory mediators exacerbates the inflammatory airway status. The potentiation 
of IL-8 release by simultaneous PAR-2 activation and LPS exposure, as observed in this 
work,  intensifies neutrophil  recruitment,  which is an example of cooperative action of 
inflammatory mediators acting in chronic inflammatory airway diseases. This supports 
the observations of others reporting a proinflammatory role of PAR-2 in airways  .  The 
participation  of  PAR-2 in  the  amplification  of  inflammatory  signaling  underlines  the 
enormous importance of this receptor in lung pathophysiology.
Investigations presented above show that the persistent activation of PAR-2 by its 
agonists  for  which  elevated  levels  have  been  observed  in  lung  disorders,  causes  up-
regulation of its own expression level. This might further increase the susceptibility and 
responsiveness  to  following activation  of  this  receptor.  The  consequence  of  all  these 
events is a substantial enhancement of IL-8 production. An alternative explanation for the 
potentiating effect of PAR-2 on the LPS-induced release of IL-8 can be the fact that LPS 
as well as PAR-2 activation independently induce expression of an additional portion of 
PAR-2 and thus enhance the responsiveness to PAR agonists. This participation of PAR-2 
in  a  positive  feedback  loop  that  amplifies  inflammatory  signaling,  underlines  the 
enormous importance of this receptor in the lung pathophysiology.
We can also speculate that the potentiation of IL-8 production, observed in our 
work,  which was induced by the combination of PAR-2 AP and LPS, is  also due  to 
increased  transcriptional  activity  of  factors  responsible  for  IL-8  transcription.  IL-8 
transcription can be regulated by several  transcription factors, including AP-1, NF-κB, 
AP-2, and NF-1L-6  (. PAR-2 activation in airway epithelial cells can induce AP-1 and 
NF-κB transcriptional activity . The same transcription factors can be activated upon LPS 
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exposure  .  We  propose  that  simultaneous  application  of  PAR-2  agonist  and  LPS  to 
epithelial cells synergistically increases transcriptional activity of AP-1 and NF-κB and 
their binding to the IL-8 promoter.
It  should  be  mentioned that  only  PAR-2,  but  not  PAR-1,  activation  by  specific 
activating peptides  leads  to release of IL-8 and is able  to  potentiate  the LPS-induced 
chemokine release from both primary epithelial cells and cell lines, what is schematically 
summarized in Figure 4.2.
Figure 4.2:  Scheme summarizing the effects of the exposure of lung epithelial cells to 
PAR agonists and LPS on IL-8 production. Application of PAR agonists  and LPS as a single 
stimulus as well as the combined application are marked on top of the scheme in boxes within 
dotted  frames.  The  effect  of  the  stimulation  of  the  cells  with  these  agonists  is  given  as 
“Response” (IL-8 synthesis). The thickness of the arrows illustrates the strength of the response. 
The dashed arrows with a cross portray the lack of influence of the respective agonist.
The observed effect of thrombin on IL-8 release, which was observed in A549 cells 
and HSAEC can be due to activation of other receptors for thrombin than PAR-1, e.g. 
PAR-3. 
However,  each  member  of  the  PAR  family  possesses  a  different  selectivity  towards 
agonists. PARs can induce different responses, depending on the agonist and cell type. 
Several  recent  reports  have  shown  that  different  PAR  subtypes  can  elicit  cellular 
responses, which are unique for this PAR. For example, in A549 cells PAR-2, but not 
PAR-1, activation resulted in PGE2 release and increased neutrophil adhesion to the cells 
in spite of the functional presence of PAR-1 . Activation of PAR-2 in normal bronchial 
epithelial cells causes changes in ion transport, while PAR-1 activation was ineffective in 
IL-8 synthesis increase
x
IL-8
expression / 
release
LPS PAR-1 AP LPS PAR-2 AP
stimulus
responses
80
Discussion
this respect . These observations can serve as an example for demonstrating distinct roles 
of PARs in lung epithelium.
4.6Inflammatory mediators and PAR activation induce TGF-β1 production.
The next part of this work aimed to assess the influence of PAR activation and LPS 
stimulation on TGF-β1 synthesis and release from lung epithelial cells. The present study 
shows for the first time enhancement of TGF-β1 mRNA expression in A549 cells upon 
PAR-1 and PAR-2 activation in A549 cells. This is consistent with the data obtained in 
human  proximal  tubule  cells  showing  that  PAR agonists  are  able  to  induce  TGF-β1 
release . Unlike PAR agonists, the bacterial component LPS displayed no effect on the 
TGF-β1 mRNA level, that is in line with a previous report . Moreover, in our study LPS 
suppressed the ability of PAR agonists to induce transcription of TGF-β1 in epithelial 
cells.
Interestingly,  a  correlation  between  modulation  of  TGF-β1  mRNA  and  PAR-2 
mRNA  synthesis  was  observed.  TGF-β1  mRNA  level  was  similarly  modified  as  the 
PAR-2 mRNA level. Activation of PARs in A549 resulted in up-regulation of PAR-2 and 
TGF-β1  mRNA.  Furthermore,  application  of  LPS,  in  addition  to  PAR  activation, 
attenuated the increase in the transcription level of PAR-2 as well as that of TGF-β1. This 
similarity possibly reveals a coupled action of PARs and TGF-β1 in the development of 
inflammatory and immunomodulatory effects in pathological conditions in the lung.
4.7 PAR-mediated  signaling  pathway  in  respiratory  epithelium.  Distinct  role  of 
MAPKs in PAR-induced IL-8 release.
There  are  multiple  intracellular  signaling  pathways  mediating  the  down-stream 
effects of GPCRs. Among them, mitogen-activated protein kinases (MAPKs) that belong 
to a family of serine/threonine kinases are important components of signal transduction 
pathways stimulated by GPCRs. They participate in diverse cellular events, including cell 
differentiation, movement and division. MAPK play also an important role in different 
immune responses in various cells, from the initiation of the immune response to inducing 
cell death . Signals of the members of the MAPK are transmitted by phosphorylation by 
their immediate upstream MEK and following translocation to the nucleus, where they 
phosphorylate  transcription  factors,  thereby  regulating  the  expression  of  genes. The 
MAPK family comprises five modules, which can signal independently from each other. 
The  best  characterized  members  are  the extracellular  signal-regulated  kinase  1 and 2 
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(ERK1/2),  c-Jun  N-terminal  kinase  (JNK)  and  p38  MAPK.  The  ERK1/2-activated 
cascade preferentially regulates  cell  growth and differentiation,  whereas JNK and p38 
MAPK participate in cascades that function mainly in stress responses, like inflammation 
and apoptosis .
Figure 4.3: A schematic overview of mammalian MAPK modules (Schaeffer and Weber, 
1999).
In this study the involvement of  MAPKs  in the IL-8 release induced by LPS and 
PAR  agonists  was  investigated.  The  MAPKs  have  been  shown  to  regulate  the  IL-8 
expression and secretion induced by various inflammatory mediators in lung epithelial 
cells  .  The  involvement  of  particular  MAPK (ERK1/2,  JNK  or  p38)  in  IL-8  release 
depends on the type of stimulus. In the present investigation, we have found that LPS-
induced IL-8 release from A549 cells does not require the activity of MAPKs. None of 
the  MAPKs  was  phosphorylated  after  stimulation  with  LPS.  However,  by 
phosphorylation  analysis  and  inhibitor  studies  we  showed  that  both  PAR-2  AP-  and 
thrombin-induced IL-8 release was dependent on ERK1/2 and JNK signaling (Fig.4.4). 
p38 MAPK was not involved in this process.
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Figure  4.4:  Activation  of  PARs  in  airway  epithelial  cells  induces  IL-8  release  via 
ERK1/2 and JNK. During lung inflammation  and injury,  besides the  presence of exogenous 
proteases from airborne allergens, there is elevated level of serine proteases from the coagulation 
system and released from the cells of the immune system. Subsequently, PARs are activated by 
these proteases inducing IL-8 release via activation of ERK1/2 and JNK but not activation of p38 
MAPK.
Our  data  on  PAR-2  activation  by  its  specific  activating  peptide  are  in  good 
agreement with recently published results on IL-8 release induced by PAR-2 activation by 
a protease from house dust mite, Der p3 .  Interestingly, in that work the involvement of 
p38 but not JNK in the IL-8 release induced by PAR-2 AP was shown. 
In our work, we found that simultaneous stimulation of A549 cells with LPS and 
PAR-2 AP or thrombin did not modify the phosphorylation levels of MAPKs compared 
to  the  effect  of  the  PAR  agonists  alone.  Pharmacological  inhibitors  of  the  MAPK 
signaling pathway showed the same inhibitory capacity in terms of IL-8 release for each 
stimulus alone and for the combination of stimuli. The inhibitor of MEK1/2, U0126, and 
the inhibitor of JNK, SP600125, both abolished the effects of thrombin and PAR-2 AP in 
A549  cells.  Therefore,  we  conclude  that  the  MAPK pathway  is  not  involved  in  the 
potentiating effect of LPS and PAR agonist in IL-8 production. However, activation of 
ERK1/2 and JNK contribute to the signaling pathway in PAR-mediated IL-8 secretion in 
A549 cells, as shown in Figure 4.4.
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4.7.1 Role of PAR-3 in IL-8 production and the signaling pathway involved in this 
process.
The intriguing question raised during our observation was the possible contribution 
of PAR-3 in thrombin-mediated IL-8 release from epithelial cells.
The patho-physiological roles of human PAR-3 are still largely unknown. Therefore 
the aim of this study was to verify whether PAR-3 participates in inflammatory reactions, 
similarly  to  other  PARs,  by  mediating  interleukin-8  production.  Furthermore,  the 
important question to be answered was whether human PAR-3 can signal autonomously 
or only in cooperation with another thrombin receptor. Finally, is should be answered if 
MAPKs are involved in PAR-3 signaling.
In  our  studies,  the  HEK-293  cells  transfected  with  the  PAR-3-GFP  served  as 
experimental model to investigate the issue mentioned above. The PAR-3-GFP construct 
showed clearly a significant rise in Ca2+ response compared to those cells transfected only 
with GFP. These data confirm that the PAR-3 used in our system was functional. Indeed, 
PAR-3 can be activated by thrombin, thereby triggering increase in [Ca2+]i. Our findings 
are in line with data obtained from PAR-3-expressing COS-7 cells and Xenopus oocytes, 
where  thrombin  induced  phosphoinositide  hydrolysis  and  45Ca  release,  respectively  . 
However  in  other  systems,  expressing  endogenous  PAR-3,  thrombin  did  not  trigger 
PAR-3 signaling. The group of Hollenberg reported the inability of thrombin to induce 
Ca2+ mobilization  after  desensitization  of  PAR-1  with  its  specific  agonist  in  cells 
expressing PAR-3, i.e. Jurkat and HEK-293 cells . Similar results were obtained in human 
brain microvascular endothelial and in human umbilical vein endothelial cells (HUVEC) . 
This inconsistency in the calcium signaling between endogenous und exogenous PAR-3 
may be due to the respective expression level of the receptor.
Further,  the  results  presented  here  demonstrate  that  thrombin  mediates  IL-8 
production  in  HEK-293  cells  stably  expressing  PAR-3.  The  cytokines  are  the  main 
effector substances  of the inflammatory and immune response.  Many common human 
diseases  are  characterized  by  a  dysregulation  of  the  balance  between  pro-  and  anti-
inflammatory cytokines. Therefore, this ability of PAR-3 to mediate the increased IL-8 
release allows us to assume that human PAR-3 is an important player in the inflammatory 
state.
Concerning the issue whether PAR-3 is able to mediate autonomously intracellular 
signaling, it has to be mentioned, that PAR-4 was not expressed in HEK-293 cells, both 
wildtype cells and cells transfected with PAR-3 receptor. This we conclude from PAR-4 
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detection by RT-PCR and measurements  of [Ca2+]i,  which both gave negative  results. 
Therefore it can be concluded that, differently from the mouse system, where PAR-3 acts 
as a cofactor for PAR-4 activation, in humans PAR-3 can generate an intracellular signal 
independent  from  PAR-4.  Additionally,  our  investigations  on  PAR-1-deficient  cells 
suggest that also the presence of PAR-1 is not necessary for PAR-3-mediated production 
of  IL-8.  The  silencing  of  the  PAR-1  expression  in  HEK-PAR3-GFP  cells  had  no 
significant  influence  on  IL-8  production  upon  thrombin  stimulation.  Moreover,  the 
application of TRag, the PAR-1-activating peptide, did not trigger the IL-8 synthesis in 
HEK-PAR3-GFP cells co-transfected with control siRNA, which thus express functional 
PAR-1. That finding underlines that PAR-1 was not involved in the IL-8 synthesis and 
that PAR-3 mediates, independently from PAR-1, IL-8 release in HEK-PAR3-GFP cells 
upon exposure to thrombin.
A  similar  effect  of  thrombin  was  seen  in  lung  epithelial  A549  cells  that 
endogenously express PAR-3. These cells responded to this protease with enhanced IL-8 
release.  On the contrary,  HBE cells  that  lack  PAR-3 expression failed  to  respond to 
thrombin  with  increasing  IL-8  production.  Although  both  cell  lines  express  PAR-1, 
PAR-1 activation by its activating peptide was not able to induce IL-8 synthesis. These 
finding can give supportive evidence that endogenous PAR-3 is susceptible to thrombin, 
which causes IL-8 production.
However,  it  has  to  be  mentioned  that  in  other  systems  such  as  human  dermal 
fibroblasts or human luteinized granulosa cells (LGC), thrombin stimulation resulted in 
increased IL-8 release via PAR-1 activation, which was proven using the PAR-1 agonist . 
It can be suggested that this PAR-1-mediated IL-8 synthesis might be due to the high 
expression level of PAR-1 in these cells. Since both cells expressed besides PAR-1, also 
PAR-3, the second alternative might be that when endogenously expressed, both receptors 
form in some part heterodimers, according to a recent report . With high expression levels 
of PAR-1, the possibility to form heterodimers with PAR-3 is increased. It seems possible 
that mainly the PAR1/PAR3 heterodimers, but not PAR1 alone, might be able to induce 
IL-8 release. 
We investigated also the involvement of  MAPKs  in the IL-8 release induced by 
thrombin  from HEK-293  cells  expressing  PAR-3.  The  MAPKs  have  been  shown  to 
regulate the IL-8 expression and secretion induced by PAR activation in many different 
cells.  Here,  we  demonstrate  for  the  first  time  that  activation  of  PAR-3  by  thrombin 
mediates IL-8 synthesis via ERK1/2 phosphorylation, whereas the other members of the 
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MAPK  family,  JNK  and  p38  MAPK,  were  not  significantly  involved  in  thrombin-
mediated PAR-3 activation. We have confirmed these observations by  phosphorylation 
analysis  and  inhibitor  studies.  Silencing  of  PAR-1  in  HEK-PAR3-GFP  cells  had  no 
significant effect on the level of ERK1/2 phosphorylation, except for a slight reduction 
after  5 min of thrombin stimulation.  These experiments  confirm that PAR-3-mediated 
signaling  does  not  require  the  presence  of  PAR-1.  However,  the  existence  of  some 
proportion of PAR-1/PAR3 heterodimers cannot be excluded. Moreover,  the relatively 
weak  but  significant  JNK  activation  and  its  involvement  in  thrombin-mediated  IL-8 
secretion might be due to PAR-1/PAR-3 co-activation. Therefore, the concept of receptor 
dimerisation might be an important  topic  that  has to be followed further in exploring 
PAR-3 signaling.  It  has been shown already that PAR-1 and PAR-4 are able to form 
stable heterodimers on human platelets and also when expressed in COS-7 fibroblasts. 
There PAR-1 acts as a cofactor and promotes the cleavage and activation of PAR-4 .
In  conclusion,  our  investigations  show  that  human  PAR-3  might  signal  after 
activation by thrombin. The functional consequence of PAR-3 activation is elevation in 
ERK1/2  phosphorylation  and  increase  in  production  of  IL-8.  Furthermore,  PAR-3 
responsiveness to thrombin is generally not dependent on the presence of PAR-1.
4.8 Conclusions
PARs on the airway epithelium can be activated  both by exogenous proteases 
accessing the epithelium and by endogenous proteases secreted from resident or recruited 
cells.  Under  pathological  conditions,  PAR-activating  proteases  as  well  as  pro-
inflammatory mediators from pathogens are present at elevated level.  We demonstrate 
that,  among  three  trypsin  isoforms,  cationic  and  anionic  isoforms  interact  with  lung 
epithelial  cells  and  activate  PAR-2.  Differently,  mesotrypsin  exhibits  no  activity  on 
epithelial PARs (Fig. 4.5).
Simultaneous  occurrence  of  PAR  activation  and  bacterial  pathogen  invasion 
represents an additional relevant issue for the better understanding of the development of 
lung infection and chronic inflammatory diseases. Our studies present new evidence for 
separate  and  cooperative  functions  of  PARs  in  the  airway  epithelial  cells  that  are 
summarized in Figure 4.5. The numbered pathways illustrated in Figure 4.5 show the 
following findings:
 Pathway 1:  The continuous activation  of  PAR-1 and PAR-2 by  their  agonists 
increases the expression level of these receptors.
86
Discussion
 Pathway 2: The bacterial endotoxin LPS activates TLR-4 that causes the increase 
of the transcription level of PAR-2, but not of PAR-1.
 Pathway  3:  The  increased  PAR-2  mRNA  level  persists  upon  simultaneous 
exposure to LPS, conditions that attenuate up-regulation of PAR-1 mRNA level.
 Pathway 4: Only activation of PAR-2 leads to increased production of chemokine 
IL-8. ERK1/2 and JNK are involved in this PAR-2 AP-mediated IL-8 release.
 Pathway 5: There is a cooperative action of PAR-2 and LPS in the production of 
the chemoattractant IL-8 and subsequent neutrophil recruitment.
 Pathway  6:  PAR-1  and  PAR-2  activation  increase  the  production  of  the 
immunomodulatory cytokine TGF-β1. PAR-2 agonist exhibits higher effect than 
PAR-1 agonist on TGF-β1 synthesis.
 Pathway  7:  The  functional  consequence  of  PAR-3  activation  by  thrombin  is 
elevation in ERK1/2 phosphorylation and increase in production of IL-8.
PAR-3, as a receptor that mediates cytokine production, can be considered as an 
important modulator in the burst of inflammatory reactions. These findings presented 
here give new insights into the signaling and function of human PAR-3. With the help 
of  HEK cells  overexpressing PAR-3 we could  confirm our  hypothesis  of  PAR-3-
mediated responses in airway epithelial cells.
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Figure 4.5: Scheme of separate and cooperative action of PARs and bacterial endotoxin (LPS) in 
regulation of the production of cytokines in airway epithelium. In lung epithelial cells PARs can 
be activated by airborne proteases and also by endogenous proteases e.g. cationic and anionic 
isoforms of trypsin that activate epithelial  PAR-2.  Pathway 1: The consequence of continuous 
activation of PAR-1 and PAR-2 is increased expression of both receptors. Pathway 2: Exposure of 
the cells to LPS up-regulates expression of PAR-2, but not of PAR-1 and PAR-3. Pathway 3: LPS 
in  combination  with  PAR-2 activation  induced increased  transcription  of  PAR-2.  Pathway 4: 
Activation of PAR-2 but not of PAR-1 triggered production of IL-8 through ERK1/2 and JNK. 
Pathway  5:  Simultaneous  LPS  and  PAR-2  activation  causes  potentiation  in  IL-8  synthesis. 
Pathway 6:  Activation  of  PARs induces  synthesis  of  TGF-β1.  Pathway 7:  Thrombin-induced 
PAR-3 activation leads to the ERK1/2 phosphorylation and finally to elevated IL-8 production.
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5 Abstract
Asthma is a chronic inflammatory disease of the airways in which besides migratory 
cells of the immune system, many resident cells like smooth muscle cells, fibroblasts and 
epithelial cells play important roles. The airway epithelium  acts not only as a physical 
barrier for inhaled infectious stimuli but also actively participates in acute and chronic 
inflammatory reactions by releasing pro- and anti-inflammatory mediators. Exposure of 
epithelial  cells  to  deleterious  factors,  like  allergens,  bacteria,  pollutants,  and  to 
endogenous  proinflammatory  factors,  triggers  defence  mechanisms  by  modulation  of 
expression  and  secretion  of  different  bioactive  molecules  such  as  lipid  mediators, 
cytokines, extracellular matrix proteins. It has been shown that the release of those agents 
is  frequently  mediated  via  activation  of  protease-activated  receptors  (PARs).  PARs 
belong  to  the  superfamily  of  G-protein  coupled  receptors  with  a  7-trans-membrane 
domain structure.  They are activated by proteolytic  cleavage of their  N-terminus.  For 
many  potential  PAR activators  in  airways elevated activity  has been  observed during 
chronic  inflammation.  Among  those  proteases  are  thrombin,  tryptase,  human  airway 
trypsin-like protease (HAT) as well as proteases from airborne allergens. However, there 
is  still  limited  information  concerning  the  question  which  particular  factors  are 
responsible for the alteration of PAR expression and susceptibility in lung epithelial cells.
The findings of the present study are as follows:
1. Using  RT-PCR,  immunocytochemistry  and  Ca  2+ mobilization  measurements,  we 
demonstrated that the airway epithelial cell line A549 expresses PAR-1, PAR-2, and 
PAR-3.  Short-term stimulation of these cells with thrombin, trypsin, and activating 
peptides of PAR-1, PAR-2, but not PAR-3 and PAR-4, induced a transient rise of 
[Ca2+]i.
2. We showed that cationic and anionic trypsin induce Ca2+ mobilization in these cells. 
Mesotrypsin displays no effect on [Ca2+]i rise. Furthermore, from desensitization study 
using PAR-2 AP we conclude that PAR-2 is substrate for cationic and anionic trypsin 
isoforms in human airway epithelial cells.
3. We evaluated the influence of inflammatory mediators LPS, TNF-α, IL-8 and PGE2 
on  PAR  expression  level  in  A549  cells.  We  also  investigated  the  influence  of 
continuous PAR activation on PAR expression and release of the proinflammatory 
chemokine IL-8. We employed three different cells, two airway epithelial cell lines, 
A549 and HBE cells  and primary  airway epithelial  cells  (HSAEC).  The bacterial 
endotoxin LPS after 4 h of stimulation up-regulated PAR-2 expression 2-fold, but the 
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effect disappeared after 24-h-term stimulation. TNF-α up-regulated PAR-1, -2 and -3 
expression after 24 h of incubation. Exposure of the cells to IL-8 slightly decreased 
PARs mRNA level, mostly PAR-2. Similarly PGE2 down-regulated PAR expression 
after 10 h of stimulation, whereas after 16 h PAR-2 mRNA level was up-regulated.
4. Continuous activation of PARs by exposure of epithelial cells to PAR-1 and PAR-2 
agonists increased the PAR-1 expression level. The PAR-2 agonist exhibited higher 
potency than PAR-1 activators. However, in epithelial cells the combined incubation 
with LPS and PAR agonists abrogated the PAR-1 up-regulation induced by a single 
stimulus. Stimulation with PAR-1 or PAR-2 agonists also up-regulated the PAR-2 
expression level (2.7-fold) that was higher than the effect of PAR agonists on PAR-1 
level. In contrast to PAR-1, the PAR-2 level remained elevated under concomitant 
stimulation with LPS and PAR-2 agonist. PAR-3 mRNA level in A549 cells remained 
unaffected upon continuous PAR activation, whereas combined stimulation with PAR 
agonists and LPS resulted in slight down-regulation of PAR-3 level after 24 h.
5. Activation of PAR-2, but not of PAR-1 caused production of IL-8 from the epithelial 
cell lines. This effect was mediated in A549 cells by c-jun N-terminal kinase (JNK) 
and  extracellular  signal  regulated  kinase-1/2  (ERK1/2).  We  found  synergistic 
modulation by PAR-2 agonist and LPS of the IL-8 synthesis and release both in the 
epithelial cell line and in primary epithelial cells.
6. PAR agonists induced also expression of the immunomodulatory cytokine TGF-β1. 
Simultaneous application of PAR agonists together with LPS attenuated or completely 
abolished the TGF-β1 up-regulation induced by PAR agonists alone.
7. With the help of HEK-293 cells expressing PAR-3, we demonstrated for the first time, 
that PAR-3 is involved in thrombin-mediated ERK1/2 activation and release of IL-8. 
Furthermore, generation of intracellular signals by PAR-3, such as enhancement of 
cytokine synthesis, does not require co-activation of PAR-1 or PAR-4. 
In summary,  these results  underline the exclusive role  of PAR-2 in human lung 
epithelial  cells  in  regulation  of  receptor  expression  and  mediating  inflammatory 
responses. We show an intricate interplay between LPS and PAR agonists in affecting 
PAR regulation and production of IL-8 and TGF-β1 in lung epithelial cells. Our study 
reveals  a  new  cooperative  action  of  PAR-2  and  endotoxin  that  contributes  to  the 
enhancement of inflammatory signaling in airways. In addition, we show that PAR-3, the 
elusive  receptor  among  the  PARs,  can  be  activated  by  thrombin  inducing  functional 
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responses, such as IL-8 synthesis. Therefore PAR-3 participates actively in inflammatory 
reactions.
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6 Zusammenfassung
Asthma ist  eine chronische,  entzündliche Erkrankung der  Atemwege,  in welcher 
neben den wandernden Zellen des Immunsystems auch die Zellen der glatten Muskulatur, 
sowie  Fibroblasten  und  Zellen  des  Epithels  eine  wichtige  Rolle  spielen.  Die 
Alveolarepithelzellen sind nicht nur ein physikalisches Hindernis für Infektionserreger, 
sondern spielen auch eine aktive Rolle in akuten und chronischen Entzündungsreaktionen, 
indem  sie  eine  Reihe  von  entzündungsauslösenden  und  -hemmenden  Mediatoren 
freisetzen.  Die  Exposition  von  Epithelzellen  gegenüber  schädlichen  Faktoren,  wie 
Allergenen,  Bakterien,  Schmutzstoffen  und  endogenen  pro-inflammatorischen  Stoffen 
lösen  Abwehrmechanismen  aus,  wodurch  Expression  und  Freisetzung  von  wichtigen 
bioaktiven  Molekülen,  wie  z.  B.  Lipidbotenstoffen,  Zytokinen,  extrazellulären 
Matrixproteinen  gesteuert  werden.  Es  wurde  gezeigt,  dass  die  Freisetzung  dieser 
Mediatoren oft durch Aktivierung von Protease-aktivierten Rezeptoren (PARs) vermittelt 
wird.  PARs gehören zu der Superfamilie der G-Protein-gekoppelten Rezeptoren mit  7 
Transmembran-Domänen. Aktivierung der PARs wird durch die proteolytische Spaltung 
durch  extrazelluläre  Proteasen  eingeleitet.  Die  Spiegel  vieler  PAR  Agonisten  in  den 
Atemwegen sind während chronischer Erkrankung erhöht. Dazu gehören die Proteasen 
wie Thrombin, Tryptase, HAT (human airway trypsin-like protease) und viele durch die 
Luft übertragene Allergene. Unsere Kenntnisse bezüglich der Faktoren, welche die PAR 
Expression und deren Erregbarkeit modifizieren, sind noch begrenzt.
In der vorliegenden Arbeit werden folgende Ergebnisse vorgestellt:
1. Wir  haben  mittels  RT-PCR,  Immunozytochemie  und  Ca2+-Mobilisierungsstudien 
gezeigt, dass PAR-1, PAR-2 und PAR-3 in Epithelzellen der Lunge (Zelllinie A549) 
funktionell  exprimiert  werden.  Kurzzeitstimulierung  dieser  Zellen  mit  Thrombin, 
Trypsin und Peptiden,  die die „tethered-ligand“-Domäne von PAR-1, PAR-2, aber 
nicht  von PAR-3 und PAR-4,  darstellen,  induzieren einen transienten  Anstieg der 
intrazellulären Ca2+-Konzentration ([Ca2+]i).
2. Unsere Untersuchungen von Isoformen des Trypsins ergaben, dass kationisches und 
anionisches  Trypsin  die  Ca2+ Mobilisierung  in  Lungen-Epithelzellen  induzieren. 
Mesotrypsin führte jedoch zu keiner [Ca2+]i-Antwort in diesen Zellen. Basierend auf 
Desensitisierungsversuchen  durch  Verwendung  des  PAR-2  Aktivierungspeptids 
(PAR-2-AP),  konnten  wir  zeigen,  dass  PAR-2  in  der  Lunge  ein  Substrat  für 
kationisches und anionisches Trypsin darstellt.
92
Zusammenfassung
3. Weitere  Untersuchungen  befassten  sich  mit  den  Änderungen  des  PAR-mRNA-
Spiegels  nach  Exposition  der  A549-Zellen  gegenüber  Entzündungsmediatoren  wie 
LPS,  TNF-α,  IL-8  und  PGE2.  Dazu  wurden  Real-Time  PCR  Experimente 
durchgeführt.  Die  Behandlung  mit  den  oben  genannten  Mediatoren  bewirkte 
unterschiedliche Effekte, wobei PAR-2 mRNA hauptsächlich beeinflusst wurde.
4. Für  weitere  Analysen  haben  wir  noch  andere  Lungenepithelzellen  eingesetzt,  wie 
HBE Zellen und primäre Lungen Epithelzellen (HSAEC).
Eine kontinuierliche Aktivierung der PARs durch Stimulierung mit PAR Agonisten führte 
zu einer erhöhten Expression von PAR-1 mRNA, wobei das PAR-2 Aktivierungspeptid, 
verglichen  mit  PAR-1-AP,  eine  höhere  Wirksamkeit  aufwies.  Allerdings  führte  die 
kombinierte Inkubation der Zellen mit PAR Agonisten und LPS zu einer verminderten 
Hochregulation von PAR-1 mRNA. PAR-2 mRNA wurde ebenfalls nach der Behandlung 
mit PAR-1 und PAR-2 Agonisten hochreguliert, und die Änderungen waren größer als die 
bei der PAR-1 Expression. Im Gegensatz zu PAR-1, war immer noch eine erhöhte PAR-2 
Expression nach gleichzeitiger Behandlung mit LPS und PAR-2 Agonist zu beobachten. 
Die PAR-3-mRNA-Expression in A549 Zellen blieb jedoch unter kontinuierlicher PAR 
Aktivierung unverändert. Nur die kombinierte Inkubation der Zellen mit LPS und PAR 
Agonisten bewirkte eine Herunterregulation der PAR-3 Expression. 
5. Weiterhin konnten wir zeigen, dass die Aktivierung von PAR-2, aber nicht die von 
PAR-1  die  Freisetzung  von  IL-8,  einem  Entzündungsmarker,  induziert.  Darüber 
hinaus wurden die Signalübertragungswege, welche nach Stimulation mit Thrombin 
und  dem  PAR-2-AP  in  A549  Zellen  aktiviert  werden,  untersucht.  Die  beiden 
Agonisten  führten  zu  einer  Aktivierung  des  MAPK-Weges,  stimulierten  die 
Phosphorylierung von ERK1/2 (extracellular signal regulated kinase-1/2) und JNK (c-
jun  N-terminal  kinase).  Außerdem  haben  wir  in  A549  Zellen  und  primären 
Lungenepithelzellen  nachgewiesen,  dass  die  durch  PAR-2-AP und LPS-vermittelte 
IL-8 Freisetzung synergistisch stimuliert wurde.
6. Zudem erhöhten PAR Agonisten, hauptsächlich PAR-2-AP, die Expression von TGF-
β1,  einem immunmodulatorischen  Zytokin.  Simultane  Behandlung  der  Zellen  mit 
LPS und PAR Agonisten  verminderte  die  durch  PAR Aktivierung hervorgerufene 
TGF-β1 Hochregulation.
7. Mit Hilfe von HEK-293 Zellen,  die PAR-3 überexprimieren,  konnten wir als erste 
zeigen,  dass  PAR-3  an  der  Thrombin-vermittelten  ERK1/2  Aktivierung  und  IL-8 
Freisetzung  beteiligt  ist.  Im  Gegensatz  zu  ERK1/2  wurde  JNK  nur  geringfügig 
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aktiviert, wobei die p38 MAPK bei der durch Thrombin induzierten Signalkaskade 
überhaupt nicht beteilig war. Die von PAR-3 vermittelten Effekte, wie die erhöhte 
IL-8 Synthese, erfordern keine Koaktivierung von PAR-1. Dieses haben wir mittels 
Herunterregulierung der Expression von PAR-1 durch siRNA bestätigen können.
Zusammenfassend  ist  diese  Studie  die  erste,  die  folgende  Befunde  über 
Epithelzellen  der  Lunge  zeigt:  i)  Die  Entzündungsmediatoren  modulieren  die  PAR 
Expression in A549 Zellen unterschiedlich. ii) Kontinuierliche PAR Aktivierung führt zur 
Änderung der PAR-Expression, wobei PAR-2 eine besonders herausragende Rolle spielt. 
iii) PAR-2 Aktivierung induziert IL-8 Freisetzung, wobei es mit LPS synergistisch wirkt. 
iv)  PAR-induzierte  IL-8  Freisetzung  wird  über  den  ERK1/2-  und  JNK-Signalweg 
vermittelt. iiv) PAR Aktivierung führt zur erhöhten TGF-β1-Expression.
Diese Studien zeigen dass PARs, insbesondere PAR-2, eine signifikante Funktion in 
entzündlichen Erkrankungen der Atemwege spielen. Das Wechselspiel zwischen PAR-2 
und Endotoxinen wie LPS gibt  wertvolle  Einblicke in das  Verständnis  der  Rolle  von 
PARs bei Erkrankungen der Lunge, wie z. B. Asthma. Zusätzlich konnten wir zeigen, 
dass Aktivierung von PAR-3, des bisher am weinigsten erforschten Mitglieds der PAR-
Familie,  zu  einer  IL-8  Freisetzung  führt,  und  dass  dieser  Rezeptor  dadurch  eine 
signifikante Rolle in Entzündungsprozessen spielen kann.
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8 Abbreviations
AP Activating peptide
A549 Human alveolar epithelial cell line
bp Base pair
BSA Bovine serum albumin
[Ca2+]i Intracellular calcium concentration
COS-7 African green monkey kidney fibroblast-like cell line
cDNA Complementary deoxyribonucleic acid
DMEM Dulbecco’s Modified Eagle’s Medium
DNA Deoxyribonucleic acid
dNTP Deoxyribonucleoside triphosphate
DEPC Diethyl pyrocarbonate
DMSO Dimethyl sulfoxide
ds Double stranded
DMSO Dimethyl sulfoxide
ELISA Enzyme Linked-Immuno-Sorbent Assay
ERK Extracellular regulated kinase
Fura-2/AM Fura-2/Acetoxymethyl Ester
FCS Fetal calf serum
GAPDH Glyceraldehyde phosphate dehydrogenase
GFP Green fluorescent protein
GPCR G-protein coupled receptor
GDP Guanosine diphosphate
GTP Guanosine triphosphate
HBE Human bronchial epithial cell line
HBSS Hank’s balanced salt solution
HEK Human embryonic kidney epithelial cell line
HSAEC Human Small Airway Epitehlial Cells
InsP3 Inositol 1,4,5-trisphosphate
JNK c-jun related kinase
KCM KCl- CaCl2- MgCl2
LB Luria bertini
MMPs Matrix Metalloproteinases
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MAPK Mitogen-activated protein kinase
mRNA Messenger ribonucleic acid
MOPS N-Morpholino-3-propansulphonic acid
p38 MAP p38 mitogen activated protein
PBS Phosphate buffered saline
PLC Phospholipase C
PAR Protease-activated receptor
PKC Protein kinase C
PCR Polymerase Chain Reaction
RT Reverse Transcription
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
SiRNA Small interfering RNA
TCM Tris/HCl- CaCl2- MgCl2
Tm Melting temperature
TRag Thrombin receptor agonist
TBE Tris-boric acid-EDTA
TE Tris-EDTA
WT Wild-type
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